Laboratory Corporation of America (LH) 10-Q 8 May 20 2020 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares shares in Millions	3 Months Ended
	Mar. 31, 2020	May 06, 2020
Document Information [Line Items]
Entity Central Index Key	0000920148
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Entity File Number	1-11353
Entity Registrant Name	LABORATORY CORPORATION OF AMERICA HOLDINGS
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3757370
Entity Address, Address Line One	358 South Main Street
Entity Address, City or Town	Burlington,
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	27215
City Area Code	336
Local Phone Number	229-1127
Title of 12(b) Security	Common Stock, $0.10 par value
Trading Symbol	LH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		97.2

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Accounts Payable, Current	$ 568.7	$ 632.3
Current assets:
Cash and cash equivalents	323.6	337.5
Accounts Receivable, after Allowance for Credit Loss, Current	1,482.2	1,543.9
Unbilled Contracts Receivable	478.1	481.4
Supplies inventories	254	244.7
Prepaid expenses and other	353.2	373.7
Total current assets	2,891.1	2,981.2
Property, plant and equipment, net	2,609.6	2,636.6
Goodwill, net	7,388.5	7,865
Intangible Assets, Net (Excluding Goodwill)	3,905.1	4,034.5
Joint venture partnerships and equity method investments	67	84.9
Deferred Income Taxes and Other Assets, Current	6.5	8.8
Other assets, net	430.6	435.4
Total assets	17,298.4	18,046.4
Liabilities, Current [Abstract]
Accrued Liabilities, Current	828.1	942.4
Deferred Revenue, Current	432.9	451
Operating Lease, Liability, Current	202.7	206.5
Finance Lease, Liability, Current	8.2	8.4
Debt, Current	417.4	415.2
Long-term debt, less current portion	2,458	2,655.8
Long-term Debt, Excluding Current Maturities	5,790.2	5,789.8
Commitments and contingent liabilities	369.4	383.2
Operating Lease, Liability, Noncurrent	609.8	596.6
Finance Lease, Liability, Noncurrent	89.3	91.1
Deferred income taxes and other tax liabilities	943.1	942.8
Noncontrolling interest	10,259.8	10,459.3
Shareholders' equity:
Common stock, 92.8 and 93.5 shares outstanding at March 31, 2013 and December 31, 2012, respectively	18.5	20.1
Additional paid-in capital	0	26.8
Retained earnings	9	9
Accumulated other comprehensive income	(7,529)	(7,903.6)
Total liabilities and shareholders' equity	(517.9)	(372.4)
Stockholders' Equity Attributable to Parent	7,020.1	7,567
Liabilities and Equity	$ 17,298.4	$ 18,046.4

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parentheticals) - USD ($) shares in Millions, $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Accounts Receivable, Allowance for Credit Loss	$ 28.9	$ 19
Shareholders' Equity:
Common stock, shares outstanding (in shares)	97.1	97.2

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues	$ 2,823.8	$ 2,791.2
Cost of Revenue	2,095.8	2,001.5
Gross Profit	728	789.7
Selling, general and administrative expenses	395.5	393.8
Amortization of intangibles and other assets	62.3	57.1
Asset Impairment Charges	437.4	0
Net restructuring and other special charges	25.4	20.6
Operating Income (Loss)	(192.6)	318.2
Other income (expenses):
Interest expense	(55)	(56.7)
Equity method income, net	(6.6)	3
Investment income	2.6	0.6
Other, net	(16.1)	(10.4)
Earnings before income taxes	(267.7)	254.7
Provision for income taxes	49.2	68.8
Net earnings	(316.9)	185.9
Less: Net earnings attributable to the noncontrolling interest	(0.3)	(0.3)
Net earnings attributable to Laboratory Corporation of America Holdings	$ (317.2)	$ 185.6
Basic earnings per common share (in dollars per share)	$ (3.27)	$ 1.88
Diluted earnings per common share (in dollars per share)	$ (3.27)	$ 1.86

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net restructuring and other special charges	$ 25.4	$ 20.6
Provision for income taxes	49.2	68.8
Net earnings	(316.9)	185.9
Other Comprehensive Earnings, Net of Tax
Foreign currency translation adjustments	(147.5)	21.6
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax	2.7	2.7
Other comprehensive earnings (loss) before tax	(144.8)	24.3
Tax effect of adjustments	(0.7)	(0.7)
Other comprehensive earnings (loss), net of tax	(145.5)	23.6
Comprehensive earnings	(462.4)	209.5
Less: Net earnings attributable to the noncontrolling interest	(0.3)	(0.3)
Comprehensive earnings attributable to Laboratory Corporation of America Holdings	$ (462.7)	$ 209.2

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited) - USD ($) $ in Millions	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Income [Member]
BALANCE at Dec. 31, 2018	$ 6,971.4	$ 11.7	$ 1,451.1	$ 7,079.8	$ (1,108.1)	$ (463.1)
Net earnings attributable to Laboratory Corporation of America Holdings	185.6	0	0	185.6	0	0
Other comprehensive earnings, net of tax	23.6	0	0	0	0	23.6
Issuance of common stock under employee stock plans	(24.7)	0	(24.7)	0	0	0
Surrender of restricted stock and performance share awards	(19.4)	0	0	0	(19.4)	0
Conversion of zero-coupon convertible debt	7.3
Stock compensation	25.5	0	25.5	0	0	0
Purchase of common stock	(100.1)	0.1	100	0	0	0
BALANCE at Mar. 31, 2019	7,111.3	11.6	1,401.3	7,265.4	(1,127.5)	(439.5)
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets	(7)	0	0	(7)	0	0
BALANCE at Dec. 31, 2019	7,567	9	26.8	7,903.6	0	(372.4)
Net earnings attributable to Laboratory Corporation of America Holdings	(317.2)	0	0	(317.2)	0	0
Other comprehensive earnings, net of tax	(145.5)	0	0	0	0	(145.5)
Issuance of common stock under employee stock plans	(26.9)	0	(26.9)	0	0	0
Surrender of restricted stock and performance share awards	(22)	0	(22)	0	0	0
Conversion of zero-coupon convertible debt	0
Stock compensation	17.9	0	17.9	0	0	0
Purchase of common stock	(100)	0	49.6	50.4	0	0
BALANCE at Mar. 31, 2020	$ 7,020.1	$ 9	$ 0	$ 7,529	$ 0	$ (517.9)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings	$ (316.9)	$ 185.9
Adjustments to reconcile net earnings to net cash provided by operating activities:
Contingent consideration adjustment	2.1
Depreciation And Amortization Of Leased Assets	57.2	61.2
Depreciation and amortization	144.6	135.5
Stock compensation	17.9	25.5
Asset Impairment Charges	437.4	0
Deferred income taxes	5.1	17.1
Other Operating Activities, Cash Flow Statement	43.3	7
Change in assets and liabilities (net of effects of acquisitions):
Increase in accounts receivable (net)	46.7	(90.8)
Increase (Decrease) in Unbilled Contract Receivable	1.1	26.4
Increase in inventories	(10.6)	3.4
Decrease in prepaid expenses and other	(3)	7.2
Decrease in accounts payable	(56.5)	(28.8)
Increase (Decrease) in Deferred Revenue	(11.2)	5.6
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities	(149.1)	(136.6)
Net cash provided by operating activities	203.8	165.8
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	(106.6)	(94.2)
Proceeds from sale of assets	7	3.9
Proceeds from Sale of Equity Method Investments	0.9	0.4
Investments in equity affiliates	(7.9)	(3.3)
Acquisition of businesses, net of cash acquired	0	(47.3)
Net cash used for investing activities	(106.6)	(140.5)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving credit facilities	151.7	133.2
Payment, Tax Withholding, Share-based Payment Arrangement	(22)	(19.4)
Net proceeds from issuance of stock to employees	26.9	24.7
Payments for Repurchase of Common Stock	(100)	(100.1)
Other Financing Cash Flows	(7.7)	(8.4)
Repayments of Lines of Credit	(151.7)	(133.2)
Net cash provided by (used for) financing activities	(102.8)	(103.2)
Effect of exchange rate changes on cash and cash equivalents	(8.3)	(0.1)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(13.9)	(78)
Cash and cash equivalents at beginning of period	337.5	426.8
Cash and cash equivalents at end of period	$ 323.6	$ 348.8

BASIS OF FINANCIAL STATEMENT PR

BASIS OF FINANCIAL STATEMENT PRESENTATION	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	BASIS OF FINANCIAL STATEMENT PRESENTATION Laboratory Corporation of America ® Holdings together with its subsidiaries (the Company) is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. The Company’s mission is to improve health and improve lives by delivering world-class diagnostic solutions, bringing innovative medicines to patients faster and using technology to provide better care. The Company serves a broad range of customers, including managed care organizations (MCOs), biopharmaceutical companies, governmental agencies, physicians and other healthcare providers (e.g., physician assistants and nurse practitioners, generally referred to herein as physicians), hospitals and health systems, employers, patients and consumers, contract research organizations (CROs), and independent clinical laboratories. The Company reports its business in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). For further financial information about these segments, see Note 16 Business Segment Information to the Condensed Consolidated Financial Statements. During the three months ended March 31, 2020 , LCD and CDD contributed approximately 60% and 40% , respectively, of revenues to the Company. The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries for which it exercises control. Long-term investments in affiliated companies in which the Company exercises significant influence, but which it does not control, are accounted for using the equity method. Investments in which the Company does not exercise significant influence (generally, when the Company has an investment of less than 20.0% and no representation on the investee's board of directors) are accounted for at fair value or at cost minus impairment adjusted for observable price changes in orderly transactions for an identical or similar investment of the same issuer for those investments that do not have readily determinable fair values. All significant inter-company transactions and accounts have been eliminated. The Company does not have any significant variable interest entities or special purpose entities whose financial results are not included in the condensed consolidated financial statements. The financial statements of the Company's operating foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated at exchange rates as of the balance sheet date. Revenues and expenses are translated at average monthly exchange rates prevailing during the period. Resulting translation adjustments are included in “Accumulated other comprehensive income.” The accompanying condensed consolidated financial statements of the Company are unaudited. In the opinion of management, all adjustments necessary for a fair statement of results of operations, cash flows, and financial position have been made. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for a full year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles. The condensed consolidated financial statements and notes are presented in accordance with the rules and regulations of the United States (U.S.) Securities and Exchange Commission (SEC) and do not contain certain information included in the Company’s 2019 Annual Report on Form 10-K (Annual Report). Therefore, these interim statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report. Recently Adopted Guidance In June 2016, the FASB issued a new accounting standard intended to provide financial statement users with more decision-useful information about expected credit losses and other commitments to extend credit held by the reporting entity. The standard replaces the incurred loss impairment methodology in current generally accepted accounting principles (GAAP) with one that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company recorded an opening retained earnings adjustment of $7.0 with the adoption of this standard on January 1, 2020. In August 2018, the FASB issued a new accounting standard to reduce, modify, and add to the disclosure requirements on fair value measurements. The Company adopted this standard effective January 1, 2020. The adoption of this standard did not have a material impact on the consolidated financial statements. In August 2018, the FASB issued a new accounting standard to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted this standard effective January 1, 2020. The adoption of this standard did not have a material impact on the consolidated financial statements. New Accounting Pronouncements In August 2018, the FASB issued a new accounting standard to reduce, modify, and add to the disclosure requirements on defined benefit pension and other postretirement plans. The standard is effective on January 1, 2021, with early adoption permitted. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements. In December 2019, the FASB issued a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective January 1, 2021, with early adoption permitted. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements. In January 2020, the FASB issued a new accounting standard to clarify the interaction of the accounting for equity securities and investments accounted for under the equity method of accounting and the accounting for certain forward contracts and purchased options. The standard is effective January 1, 2021. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements. In March 2020, the FASB issued a new accounting standard to provide optional expedients and exceptions if certain conditions are met for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The expedients and exceptions in the standard are effective between March 12, 2020 and December 31, 2022. The Company did not elect to apply any of the expedients or exceptions for the period ended March 31, 2020 and is currently evaluating the impact this new standard will have on the consolidated financial statements. Novel Coronavirus (COVID-19) Financial Statement Impact In March 2020, the novel strain of coronavirus, now known as COVID-19, was declared a pandemic. The COVID-19 pandemic has and continues to have an extensive impact on the global health and economic environments. By mid-March 2020, government restrictions, social distancing guidelines, and overall customer caution associated with the COVID-19 pandemic negatively affected LCD’s revenues and CDD's operations. For LCD, reduction in demand impacted testing volumes broadly but was more heavily weighted towards routine tests. This reduction in demand impacted testing volumes broadly but was more heavily weighted towards routine tests. The performance of CDD has also been negatively affected by the COVID-19 pandemic through numerous study site closures around the world as well as customer initiated delays for new patient recruitment for existing clinical trials and start-up of new clinical trials. As a result of the impact of the COVID-19 pandemic, during the three months ended March 31, 2020 , the Company recorded goodwill and other asset impairment charges of $437.4 : $426.4 within CDD and $11.0 within LCD. See Note 6 Goodwill and Intangible Assets for discussion of goodwill and intangible asset impairment and Note 2 Revenue for the discussion of credit losses and additional price concessions. The Company also wrote-off or wrote down certain of the Company's investments by $ 20.2 due to the impact of COVID-19, $ 7.1 included in Equity method earnings (loss), net and $13.1 included in Other, net. Use of Estimates The extent to which the COVID-19 pandemic impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of March 31, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s implicit price concessions and credit losses, equity investments, software, notes receivable and the carrying value of goodwill and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods.
Basis of Presentation and Significant Accounting Policies [Text Block]	BASIS OF FINANCIAL STATEMENT PRESENTATION Laboratory Corporation of America ® Holdings together with its subsidiaries (the Company) is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. The Company’s mission is to improve health and improve lives by delivering world-class diagnostic solutions, bringing innovative medicines to patients faster and using technology to provide better care. The Company serves a broad range of customers, including managed care organizations (MCOs), biopharmaceutical companies, governmental agencies, physicians and other healthcare providers (e.g., physician assistants and nurse practitioners, generally referred to herein as physicians), hospitals and health systems, employers, patients and consumers, contract research organizations (CROs), and independent clinical laboratories. The Company reports its business in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). For further financial information about these segments, see Note 16 Business Segment Information to the Condensed Consolidated Financial Statements. During the three months ended March 31, 2020 , LCD and CDD contributed approximately 60% and 40% , respectively, of revenues to the Company. The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries for which it exercises control. Long-term investments in affiliated companies in which the Company exercises significant influence, but which it does not control, are accounted for using the equity method. Investments in which the Company does not exercise significant influence (generally, when the Company has an investment of less than 20.0% and no representation on the investee's board of directors) are accounted for at fair value or at cost minus impairment adjusted for observable price changes in orderly transactions for an identical or similar investment of the same issuer for those investments that do not have readily determinable fair values. All significant inter-company transactions and accounts have been eliminated. The Company does not have any significant variable interest entities or special purpose entities whose financial results are not included in the condensed consolidated financial statements. The financial statements of the Company's operating foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated at exchange rates as of the balance sheet date. Revenues and expenses are translated at average monthly exchange rates prevailing during the period. Resulting translation adjustments are included in “Accumulated other comprehensive income.” The accompanying condensed consolidated financial statements of the Company are unaudited. In the opinion of management, all adjustments necessary for a fair statement of results of operations, cash flows, and financial position have been made. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for a full year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles. The condensed consolidated financial statements and notes are presented in accordance with the rules and regulations of the United States (U.S.) Securities and Exchange Commission (SEC) and do not contain certain information included in the Company’s 2019 Annual Report on Form 10-K (Annual Report). Therefore, these interim statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report.

EARNINGS PER SHARE

EARNINGS PER SHARE	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS (LOSS) PER SHARE Basic earnings (loss) per share is computed by dividing net earnings attributable to Laboratory Corporation of America Holdings by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net earnings including the impact of dilutive adjustments by the weighted average number of common shares outstanding plus potentially dilutive shares, as if they had been issued at the earlier of the date of issuance or the beginning of the period presented. Potentially dilutive common shares result primarily from the Company’s outstanding stock options, restricted stock awards, restricted stock units, and performance share awards. The following represents a reconciliation of basic earnings (loss) per share to diluted earnings (loss) per share: Three Months Ended March 31, 2020 2019 Earnings (Loss) Shares Per Share Amount Earnings Shares Per Share Amount Basic earnings (loss) per share: Net earnings (loss) $ (317.2 ) 97.2 $ (3.27 ) $ 185.6 98.6 $ 1.88 Dilutive effect of employee stock options and awards — — — 0.9 Net earnings (loss) including impact of dilutive adjustments (a) $ (317.2 ) 97.2 $ (3.27 ) $ 185.6 99.5 $ 1.86 (a) Due to the Company's net loss for the three months ended March 31, 2020 , diluted earnings (loss) per share is the same as basic earnings (loss) per share. Diluted earnings per share represent the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. These potential shares include dilutive stock options and unissued restricted stock awards. The following table summarizes the potential common shares not included in the computation of diluted earnings per share because their impact would have been antidilutive: Three Months Ended March 31, 2020 2019 Employee stock options and awards 1.3 0.3

RESTRUCTURING AND OTHER SPECIAL

RESTRUCTURING AND OTHER SPECIAL CHARGES	3 Months Ended
	Mar. 31, 2020
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	RESTRUCTURING AND OTHER CHARGES During the three months ended March 31, 2020 , the Company recorded net restructuring and other charges of $25.4 : $8.1 within LCD and $17.3 within CDD. The charges were comprised of $5.1 related to severance and other personnel costs, $4.7 for a CDD lab facility impairment, and $15.8 in facility closures, impairment of operating lease right-of use assets and general integration activities. The charges were offset by the reversal of previously established liability of $0.2 in unused facility-related costs. During the three months ended March 31, 2019 , the Company recorded net restructuring and other charges of $20.6 : $13.1 within LCD and $7.5 within CDD. The charges were comprised of $16.8 related to severance and other personnel costs and $3.3 in costs associated with facility closures, impairment of operating lease right-of-use assets and general integration initiatives. The charges were increased by the adjustment of previously established reserves of $0.5 in severance reserves. The following represents the Company’s restructuring reserve activities for the period indicated: LCD CDD Severance and Other Employee Costs Facility Costs Severance and Other Employee Costs Facility Costs Total Balance as of December 31, 2019 $ 0.5 $ 2.7 $ 5.5 $ 4.7 $ 13.4 Restructuring charges 2.1 1.5 2.5 2.7 8.8 Adjustments to prior restructuring accruals (0.1 ) (0.2 ) 0.6 — 0.3 Impairment of lab facility — — — 4.7 4.7 Impairment of operating lease right-of-use asset — 4.8 — 6.8 11.6 Cash payments and other adjustments (0.3 ) (8.7 ) (4.4 ) (12.2 ) (25.6 ) Balance as of March 31, 2020 $ 2.2 $ 0.1 $ 4.2 $ 6.7 $ 13.2 Current $ 7.8 Non-current 5.4 $ 13.2

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	GOODWILL AND INTANGIBLE ASSETS The changes in the carrying amount of goodwill for the nine months ended March 31, 2020 , are as follows: LCD CDD Total Balance as of January 1, 2020 $ 3,721.5 $ 4,143.5 $ 7,865.0 Impairment (3.7 ) (418.7 ) (422.4 ) Foreign currency impact and other adjustments to goodwill (6.6 ) (47.5 ) (54.1 ) Balance as of March 31, 2020 $ 3,711.2 $ 3,677.3 $ 7,388.5 The Company assesses goodwill and indefinite-lived intangibles for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Based upon the revised forecasted revenues and operating income following the declaration of the COVID-19 global pandemic, management concluded there was a triggering event and updated its annual 2019 goodwill impairment testing as of March 31, 2020, for two of its CDD reporting units, including one where the 2019 fair value exceeded carrying value by approximately 10% , and two of its LCD reporting units. Based on the quantitative impairment assessment, the Company concluded that the fair value was less than carrying value for two of its reporting units and recorded a goodwill impairment of $418.7 for the CDD segment and $3.7 for LCD segment. The Company utilized a combination of income and market approaches to determine the fair value of the CDD reporting units. Based upon the results of the quantitative assessments, the Company concluded that the fair value was less than its carrying value for one of the CDD reporting units. A non-cash charge of $418.7 was recognized and included in goodwill and other asset impairments on the Consolidated Statement of Operations to reduce the carrying amount of goodwill for the CDD reporting unit to fair value. Following the impairment charge, the carrying value of goodwill for this reporting unit is $1,554.7 . The other CDD reporting unit evaluated indicated a fair value that exceeded carrying value by less than 10% . Management notes that a 1% change in the discount rate would reduce the headroom to approximately 2.0% . Goodwill for this reporting unit as of March 31, 2020 is $631.9 . The Company utilized the income approach to determine the fair value of the LCD reporting units. Based upon the results of the quantitative assessments, the Company concluded the fair value of one of the reporting units was less than its carrying value. A non-cash charge of $3.7 was recognized and included in goodwill and other asset impairments on the Consolidated Statement of Operations to reduce the carrying amount of goodwill for this LCD reporting unit to zero. The other LCD reporting unit evaluated indicated a fair value that exceeded carrying value by less than 10.0% . Management notes that a 1% change in the discount rate would cause the fair value to be less than carrying value and would result in an impairment of approximately $40.0 . Goodwill and indefinite-lived intangibles of Canadian licenses for this reporting unit as of March 31, 2020 were $81.5 and $444.1 , respectively. Although the Company believes that the current assumptions and estimates used in its goodwill analysis are reasonable, supportable, and appropriate, continued efforts to maintain or improve the performance of this business could be impacted by unfavorable or unforeseen changes which could impact the existing assumptions used in the impairment analysis. Various factors could reasonably be expected to unfavorably impact existing assumptions: primarily delays in new customer bookings and the related delay in revenue from new customers, increases in customer termination activity or increases in operating costs. In addition, given the ongoing and rapidly changing nature of the COVID-19 pandemic, there is significant uncertainty regarding the duration and severity of the pandemic as well as any future government restrictions, which may unfavorably impact existing assumptions. Accordingly, there can be no assurance that the estimates and assumptions made for the purposes of the goodwill impairment analysis will prove to be accurate predictions of future performance. The Company will continue to monitor the financial performance of and assumptions for its reporting units. Management's impairment analysis utilizes significant judgments and assumptions related to the market comparable method analysis, such as selected market multiples, and those related to cash flow projections, such as revenue and terminal growth rates, projected operating margin, and the discount rate. A significant increase in the discount rate, decrease in the revenue and terminal growth rates, decreased operating margin, or substantial reductions in end markets and volume assumptions, could have a negative impact on the estimated fair value of the reporting units. A future impairment charge for goodwill or intangible assets could have a material effect on the Company's consolidated financial position and results of operations. The components of identifiable intangible assets are as follows: March 31, 2020 December 31, 2019 Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Customer relationships $ 4,414.4 $ (1,371.0 ) $ 3,043.4 $ 4,441.7 $ (1,329.5 ) $ 3,112.2 Patents, licenses and technology 444.4 (238.7 ) 205.7 453.6 (235.7 ) 217.9 Non-compete agreements 90.7 (62.3 ) 28.4 90.9 (60.5 ) 30.4 Trade name 407.3 (228.8 ) 178.5 408.2 (219.9 ) 188.3 Land use right 10.8 (5.8 ) 5.0 10.9 (5.5 ) 5.4 Canadian licenses 444.1 — 444.1 480.3 — 480.3 $ 5,811.7 $ (1,906.6 ) $ 3,905.1 $ 5,885.6 $ (1,851.1 ) $ 4,034.5 The Company recorded a non-cash charge of $2.7 for the impairment of a CDD tradename during the three months ended March, 31, 2020. Amortization of intangible assets for the three months ended March 31, 2020 , and 2019 , was $62.3 and $57.1 , respectively. Amortization expense for the net carrying amount of intangible assets is estimated to be $176.6 for the remainder of fiscal 2020 , $ 231.8 in fiscal 2021 , $225.9 in fiscal 2022 , $222.8 in fiscal 2023 , $218.2 in fiscal 2024 , and $2,299.9

DEBT

DEBT	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Debt	DEBT Short-term borrowings and the current portion of long-term debt at March 31, 2020 , and December 31, 2019 , consisted of the following: March 31, December 31, 2019 4.625% senior notes due 2020 $ 415.5 $ 413.7 Debt issuance costs (0.3 ) (0.7 ) Current portion of note payable 2.2 2.2 Total short-term borrowings and current portion of long-term debt $ 417.4 $ 415.2 Long-term debt at March 31, 2020 , and December 31, 2019 , consisted of the following: March 31, December 31, 2019 3.20% senior notes due 2022 $ 500.0 $ 500.0 3.75% senior notes due 2022 500.0 500.0 4.00% senior notes due 2023 300.0 300.0 3.25% senior notes due 2024 600.0 600.0 3.60% senior notes due 2025 1,000.0 1,000.0 3.60% senior notes due 2027 600.0 600.0 4.70% senior notes due 2045 900.0 900.0 2.30% senior notes due 2024 400.0 400.0 2.95% senior notes due 2029 650.0 650.0 2019 Term Loan 375.0 375.0 Debt issuance costs (41.3 ) (42.2 ) Note payable 6.5 7.0 Total long-term debt $ 5,790.2 $ 5,789.8 Credit Facilities On June 3, 2019, the Company entered into a new $850.0 2019 term loan facility that matures on June 3, 2021. The 2019 term loan facility accrues interest at a per annum rate equal to, at the Company's election, either a LIBOR rate plus a margin ranging from 0.55% to 1.175% , or a base rate determined according to a prime rate or federal funds rate plus a margin ranging from 0.0% to 0.175% . The 2019 term loan balance at March 31, 2020 and December 31, 2019 , was $375.0 and $375.0 , respectively. As of March 31, 2020 , the effective interest rate on the 2019 term loan was 1.79% . The Company also maintains a senior revolving credit facility consisting of a five-year facility in the principal amount of up to $1,000.0 , with the option of increasing the facility by up to an additional $350.0 , subject to the agreement of one or more new or existing lenders to provide such additional amounts and certain other customary conditions. The revolving credit facility also provides for a subfacility of up to $100.0 for swing line borrowings and a subfacility of up to $150.0 for issuances of letters of credit. The Company is required to pay a facility fee on the aggregate commitments under the revolving credit facility, at a per annum rate ranging from 0.00% to 0.25% . The revolving credit facility is permitted to be used for general corporate purposes, including working capital, capital expenditures, funding of share repurchases and certain other payments, acquisitions and other investments. There were no balances outstanding on the Company's current revolving credit facility at March 31, 2020 , and December 31, 2019 . As of March 31, 2020 , the effective interest rate on the revolving credit facility was 1.97% . The credit facility expires on September 15, 2022. Under the term loan facility and the revolving credit facility, the Company is subject to negative covenants limiting subsidiary indebtedness and certain other covenants typical for investment grade-rated borrowers, and the Company is required to maintain certain leverage ratios. The Company was in compliance with all covenants in the term loan facility and the revolving credit facility at March 31, 2020 and expects that it will remain in compliance with its existing debt covenants for the next twelve months. The Company's availability of $923.7 at March 31, 2020 , under its revolving credit facility reflects a reduction equivalent to the amount of the Company's outstanding letters of credit. Liquidity During the fourth quarter of 2020, $412.2 of the Company's senior notes will become payable. The Company maintains investment grade debt ratings, has strong relationships with key banks, and believes that it will be able to repay these notes with available cash on hand, cash generated from operations, borrowings under its revolving credit facility, or by refinancing the notes in the public debt market. At March 31, 2020, the Company had $323.6 of cash and $923.7 of available borrowings under its revolving credit facility, which does not mature until 2022, and the Company was in compliance with all of its debt covenants. In May 2020, in order to obtain increased financial covenant flexibility, the Company and its lenders entered into amendments to the term loan facility and the revolving credit facility to increase the maximum leverage ratio to 5.0 x debt to last twelve months EBITDA for the three month periods ending June 30, September 30 and December 31, 2020 and 4.5 x for the three month period ended March 31, 2021. The amendments also provide that during any period in which the Company's leverage ratio exceeds 4.5 x debt to last twelve months EBITDA (i) the company will be prohibited from consummating share repurchases, subject to limited exceptions, (ii) borrowings under the revolving credit facility will accrue interest at a per annum rate equal to, at the Company's election, either a LIBOR rate plus a margin of 1.25% or a base rate plus a margin of 0.25% , (iii) the facility fee that the Company is required to pay on the aggregate commitments under the revolving credit facility will be 0.25% per annum, and (iv) borrowings under the term loan facility will accrue interest at a per annum rate equal to, at the Company's election, either a LIBOR rate plus a margin of 1.175% or a base rate plus a margin of 0.175% . The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business. In the second half of March, daily volume for routine tests started to decline and may continue to decline as a result of decreased consumer demand driven by a significant reduction in physician office visits, the cancellation of elective medical procedures, and the negative impacts on discretionary spending resulting from the economic downturn, among other factors. In addition, the Company has experienced numerous study site closures around the world as well as delays for new patient recruitment for existing clinical trials and start-up of new clinical trials. The significance of the impact on the Company’s business is not yet certain and depends on numerous evolving factors that the Company may not be able to accurately predict.

PREFERRED STOCK AND COMMON SHAR

PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2020
Stockholders' Equity Note [Abstract]
Changes in common shares issued and held in treasury	The changes in common shares issued are summarized below: Issued and Outstanding Common shares at December 31, 2019 97.2 Common stock issued under employee stock plans 0.5 Retirement of common stock (0.6 ) Common shares at March 31, 2020 97.1
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	The components of accumulated other comprehensive earnings (loss) are as follows: Foreign Currency Translation Adjustments Net Benefit Plan Adjustments Accumulated Other Comprehensive Earnings (Loss) Balance as of December 31, 2019 $ (285.4 ) $ (87.0 ) $ (372.4 ) Current year adjustments (147.5 ) 2.7 (144.8 ) Tax effect of adjustments — (0.7 ) (0.7 ) Balance as of March 31, 2020 $ (432.9 ) $ (85.0 ) $ (517.9 )
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred Stock and Common Shareholders' Equity	PREFERRED STOCK AND COMMON SHAREHOLDERS’ EQUITY The Company is authorized to issue up to 265.0 shares of common stock, par value $0.10 per share. The Company is authorized to issue up to 30.0 shares of preferred stock, par value $0.10 per share. There were no preferred shares outstanding as of March 31, 2020 and December 31, 2019 . The changes in common shares issued are summarized below: Issued and Outstanding Common shares at December 31, 2019 97.2 Common stock issued under employee stock plans 0.5 Retirement of common stock (0.6 ) Common shares at March 31, 2020 97.1 Share Repurchase Program At the end of 2019, the Company had outstanding authorization from the board of directors to purchase $900.0 of Company common stock. During three months ended March 31, 2020 , the Company purchased 0.6 shares of its common stock at an average price of $178.85 for a total cost of $100.0 . When the Company repurchases shares, the amount paid to repurchase the shares in excess of the par or stated value is allocated to additional paid-in-capital unless subject to limitation or the balance in additional paid-in-capital is exhausted. Remaining amounts are recognized as a reduction in retained earnings. As of March 31, 2020 , the Company had outstanding authorization from the board of directors to purchase up to $800.0 of the Company's common stock. The repurchase authorization has no expiration date, however the Company has temporarily suspended stock repurchases due to the impact of the COVID-19 pandemic. Accumulated Other Comprehensive Earnings The components of accumulated other comprehensive earnings (loss) are as follows: Foreign Currency Translation Adjustments Net Benefit Plan Adjustments Accumulated Other Comprehensive Earnings (Loss) Balance as of December 31, 2019 $ (285.4 ) $ (87.0 ) $ (372.4 ) Current year adjustments (147.5 ) 2.7 (144.8 ) Tax effect of adjustments — (0.7 ) (0.7 ) Balance as of March 31, 2020 $ (432.9 ) $ (85.0 ) $ (517.9 )

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The Company does not recognize a tax benefit unless it concludes that it is more likely than not that the benefit will be sustained on audit by the taxing authority based solely on the technical merits of the associated tax position. If the recognition threshold is met, the Company recognizes a tax benefit measured at the largest amount of the tax benefit that it believes is greater than 50% likely to be realized. The gross unrecognized income tax benefits were $32.3 and $31.7 at March 31, 2020 and December 31, 2019 , respectively. It is anticipated that the amount of the unrecognized income tax benefits will change within the next 12 months; however, these changes are not expected to have a significant impact on the results of operations, cash flows or the financial position of the Company. As of March 31, 2020 and December 31, 2019 , $32.3 and $31.7 , respectively, are the approximate amounts of gross unrecognized income tax benefits that, if recognized, would favorably affect the effective income tax rate in future periods. The Company recognizes interest and penalties related to unrecognized income tax benefits in income tax expense. Accrued interest and penalties related to uncertain tax positions totaled $6.0 and $5.5 as of March 31, 2020 and December 31, 2019 , respectively. The Company has substantially concluded all U.S. federal income tax matters for years through 2015. Substantially all material state and local, and foreign income tax matters have been concluded through 2014 and 2010, respectively. The Company has various state and foreign income tax examinations ongoing throughout the year. The Company believes adequate provisions have been recorded related to all open tax years.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES The Company is involved from time to time in various claims and legal actions, including arbitrations, class actions, and other litigation (including those described in more detail below), arising in the ordinary course of business. Some of these actions involve claims that are substantial in amount. These matters include, but are not limited to, intellectual property disputes; commercial and contract disputes; professional liability claims; employee-related matters; and inquiries, including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payers and MCOs reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company receives civil investigative demands or other inquiries from various governmental bodies in the ordinary course of its business. Such inquiries can relate to the Company or other parties, including physicians and other health care providers. The Company works cooperatively to respond to appropriate requests for information. The Company also is named from time to time in suits brought under the qui tam provisions of the False Claims Act and comparable state laws. These suits typically allege that the Company has made false statements and/or certifications in connection with claims for payment from U.S. federal or state healthcare programs. The suits may remain under seal (hence, unknown to the Company) for some time while the government decides whether to intervene on behalf of the qui tam plaintiff. Such claims are an inevitable part of doing business in the healthcare field today. The Company believes that it is in compliance in all material respects with all statutes, regulations, and other requirements applicable to its commercial laboratory operations and drug development support services. The healthcare diagnostics and drug development industries are, however, subject to extensive regulation, and the courts have not interpreted many of the applicable statutes and regulations. Therefore, the applicable statutes and regulations could be interpreted or applied by a prosecutorial, regulatory, or judicial authority in a manner that would adversely affect the Company. Potential sanctions for violation of these statutes and regulations include significant civil and criminal penalties, fines, the loss of various licenses, certificates and authorizations, additional liabilities from third-party claims, and/or exclusion from participation in government programs. Many of the current claims and legal actions against the Company are in preliminary stages, and many of these cases seek an indeterminate amount of damages. The Company records an aggregate legal reserve, which is determined using calculations based on historical loss rates and assessment of trends experienced in settlements and defense costs. In accordance with FASB Accounting Standards Codification Topic 450 “Contingencies,” the Company establishes reserves for judicial, regulatory, and arbitration matters outside the aggregate legal reserve if and when those matters present loss contingencies that are both probable and estimable and would exceed the aggregate legal reserve. When loss contingencies are not both probable and estimable, the Company does not establish separate reserves. The Company is unable to estimate a range of reasonably probable loss for the proceedings described in more detail below in which damages either have not been specified or, in the Company's judgment, are unsupported and/or exaggerated and (i) the proceedings are in early stages; (ii) there is uncertainty as to the outcome of pending appeals or motions; (iii) there are significant factual issues to be resolved; and/or (iv) there are novel legal issues to be presented. For these proceedings, however, the Company does not believe, based on currently available information, that the outcomes will have a material adverse effect on the Company's financial condition, though the outcomes could be material to the Company's operating results for any particular period, depending, in part, upon the operating results for such period. As previously reported, the Company responded to an October 2007 subpoena from the U.S. Department of Health & Human Services Office of Inspector General's regional office in New York. On August 17, 2011, the U.S. District Court for the Southern District of New York unsealed a False Claims Act lawsuit, United States of America ex rel. NPT Associates v. Laboratory Corporation of America Holdings , which alleges that the Company offered UnitedHealthcare kickbacks in the form of discounts in return for Medicare business. The Plaintiff's Third Amended Complaint further alleges that the Company's billing practices violated the False Claims Acts of 14 states and the District of Columbia. The lawsuit seeks actual and treble damages and civil penalties for each alleged false claim, as well as recovery of costs, attorney's fees, and legal expenses. Neither the U.S. government nor any state government has intervened in the lawsuit. The Company's Motion to Dismiss was granted in October 2014 and Plaintiff was granted the right to replead. On January 11, 2016, Plaintiff filed a motion requesting leave to file an amended complaint under seal and to vacate the briefing schedule for the Company's Motion to Dismiss, while the government reviews the amended complaint. The Court granted the motion and vacated the briefing dates. Plaintiff then filed the Amended Complaint under seal. The Company will vigorously defend the lawsuit. In addition, the Company has received various other subpoenas since 2007 related to Medicaid billing. In October 2009, the Company received a subpoena from the State of Michigan Department of Attorney General seeking documents related to its billing to Michigan Medicaid. The Company cooperated with this request. In October 2013, the Company received a Civil Investigative Demand from the State of Texas Office of the Attorney General requesting documents related to its billing to Texas Medicaid. The Company cooperated with this request. On October 5, 2018, the Company received a second Civil Investigative Demand from the State of Texas Office of the Attorney General requesting documents related to its billing to Texas Medicaid. The Company is cooperating with this request. On August 31, 2015, the Company was served with a putative class action lawsuit, Patty Davis v. Laboratory Corporation of America, et al., filed in the Circuit Court of the Thirteenth Judicial Circuit for Hillsborough County, Florida. The complaint alleges that the Company violated the Florida Consumer Collection Practices Act by billing patients who were collecting benefits under the Workers' Compensation Statutes. The lawsuit seeks injunctive relief and actual and statutory damages, as well as recovery of attorney's fees and legal expenses. In April 2017, the Circuit Court granted the Company’s Motion for Judgment on the Pleadings. The Plaintiff appealed the Circuit Court’s ruling to the Florida Second District Court of Appeal. On October 16, 2019, the Court of Appeal reversed the Circuit Court’s dismissal, but certified a controlling issue of Florida law to the Florida Supreme Court. On February 17, 2020, the Florida Supreme Court accepted jurisdiction of the lawsuit. The Company will vigorously defend the lawsuit. In December 2014, the Company received a Civil Investigative Demand issued pursuant to the U.S. False Claims Act from the U.S. Attorney's Office for South Carolina, which requested information regarding alleged remuneration and services provided by the Company to physicians who also received draw and processing/handling fees from competitor laboratories Health Diagnostic Laboratory, Inc. (HDL) and Singulex, Inc. (Singulex). The Company cooperated with the request. On April 4, 2018, the U.S. District Court for the District of South Carolina, Beaufort Division, unsealed a False Claims Act lawsuit, United States of America ex rel. Scarlett Lutz, et al. v. Laboratory Corporation of America Holdings , which alleges that the Company's financial relationships with referring physicians violate federal and state anti-kickback statutes. The Plaintiffs' Fourth Amended Complaint further alleges that the Company conspired with HDL and Singulex in violation of the Federal False Claims Act and the California and Illinois insurance fraud prevention acts by facilitating HDL's and Singulex's offers of illegal inducements to physicians and the referral of patients to HDL and Singulex for laboratory testing. The lawsuit seeks actual and treble damages and civil penalties for each alleged false claim, as well as recovery of costs, attorney's fees, and legal expenses. Neither the U.S. government nor any state government has intervened in the lawsuit. The Company filed a Motion to Dismiss seeking the dismissal of the claims asserted under the California and Illinois insurance fraud prevention statutes, the conspiracy claim, the reverse False Claims Act claim, and all claims based on the theory that the Company performed medically unnecessary testing. On January 16, 2019, the Court entered an order granting in part and denying in part the Motion to Dismiss. The Court dismissed the Plaintiffs' claims based on the theory that the Company performed medically unnecessary testing, the claims asserted under the California and Illinois insurance fraud prevention statutes, and the reverse False Claims Act claim. The Court denied the Motion to Dismiss as to the conspiracy claim. The Company will vigorously defend the lawsuit. Prior to the Company's acquisition of Sequenom, Inc. (Sequenom) between August 15, 2016, and August 24, 2016, six putative class-action lawsuits were filed on behalf of purported Sequenom stockholders (captioned Malkoff v. Sequenom, Inc., et al., No. 16-cv-02054- JAH-BLM , Gupta v. Sequenom, Inc., et al ., No. 16-cv-02084-JAH-KSC, Fruchter v. Sequenom, Inc., et al ., No. 16-cv-02101- WQH-KSC, Asiatrade Development Ltd. v. Sequenom, Inc., et al. , No. 16-cv-02113-AJB-JMA, Nunes v. Sequenom, Inc., et al. , No. 16-cv-02128-AJB-MDD, and Cusumano v. Sequenom, Inc., et al. , No. 16-cv-02134-LAB-JMA) in the U.S. District Court for the Southern District of California challenging the acquisition transaction. The complaints asserted claims against Sequenom and members of its board of directors (the Individual Defendants). The Nunes action also named the Company and Savoy Acquisition Corp. (Savoy), a wholly owned subsidiary of the Company, as defendants. The complaints alleged that the defendants violated Sections 14(e), 14(d)(4) and 20 of the Securities Exchange Act of 1934 by failing to disclose certain allegedly material information. In addition, the complaints in the Malkoff action, the Asiatrade action, and the Cusumano action alleged that the Individual Defendants breached their fiduciary duties to Sequenom shareholders. The actions sought, among other things, injunctive relief enjoining the merger. On August 30, 2016, the parties entered into a Memorandum of Understanding (MOU) in each of the above-referenced actions. On September 6, 2016, the Court entered an order consolidating for all pre-trial purposes the six individual actions described above under the caption In re Sequenom, Inc. Shareholder Litig. , Lead Case No. 16-cv-02054-JAH-BLM, and designating the complaint from the Malkoff action as the operative complaint for the consolidated action. On November 11, 2016, two competing motions were filed by two separate stockholders (James Reilly and Shikha Gupta) seeking appointment as lead plaintiff under the terms of the Private Securities Litigation Reform Act of 1995. On June 7, 2017, the Court entered an order declaring Mr. Reilly as the lead plaintiff and approving Mr. Reilly's selection of lead counsel. The parties agree that the MOU has been terminated. The Plaintiffs filed a Consolidated Amended Class Action Complaint on July 24, 2017, and the Defendants filed a Motion to Dismiss, which remains pending. On March 13, 2019, the Court stayed the action in its entirety pending the U.S. Supreme Court's anticipated decision in Emulex Corp. v. Varjabedian . On April 23, 2019, however, the U.S. Supreme Court dismissed the writ of certiorari in Emulex as improvidently granted. The Company will vigorously defend the lawsuit. On March 10, 2017, the Company was served with a putative class action lawsuit, Victoria Bouffard, et al. v. Laboratory Corporation of America Holdings , filed in the U.S. District Court for the Middle District of North Carolina. The complaint alleges that the Company's patient list prices unlawfully exceed the rates negotiated for the same services with private and public health insurers in violation of various state consumer protection laws. The lawsuit also alleges breach of implied contract or quasi-contract, unjust enrichment, and fraud. The lawsuit seeks statutory, exemplary, and punitive damages, injunctive relief, and recovery of attorney's fees and costs. In May 2017, the Company filed a Motion to Dismiss Plaintiffs' Complaint and Strike Class Allegations; the Motion to Dismiss was granted in March 2018 without prejudice. On October 10, 2017, a second putative class action lawsuit, Sheryl Anderson, et al. v. Laboratory Corporation of America Holdings , was filed in the U.S. District Court for the Middle District of North Carolina. The complaint contained similar allegations and sought similar relief to the Bouffard complaint, and added additional counts regarding state consumer protection laws. On August 10, 2018, the Plaintiffs filed an Amended Complaint, which consolidated the Bouffard and Anderson actions. On September 10, 2018, the Company filed a Motion to Dismiss Plaintiffs' Amended Complaint and Strike Class Allegations. On August 16, 2019, the court entered an order granting in part and denying in part the Motion to Dismiss the Amended Complaint, and denying the Motion to Strike the Class Allegations. The Company will vigorously defend the lawsuit. On December 20, 2018, the Company was served with a putative class action lawsuit, Feckley v. Covance Inc., et al ., filed in the Superior Court of California, County of Orange. The complaint alleges that Covance Inc. violated the California Labor Code and California Business & Professions Code by failing to properly pay commissions to employees under a sales incentive compensation plan upon their termination of employment. The lawsuit seeks monetary damages, civil penalties, punitive damages, and recovery of attorney’s fees and costs. On January 22, 2018, the case was removed to the U.S. District Court for the Central District of California. On February 27, 2020, the court entered an order dismissing the class action claims, and the parties settled the remaining individual claim. On April 1, 2019, Covance Research Products was served with a Grand Jury Subpoena issued by the Department of Justice (DOJ) in Miami, Florida requiring the production of documents related to the importation into the United States of live non-human primate shipments originating from or transiting through China, Cambodia, and/or Vietnam from April 1, 2014 through March 28, 2019. The Company is cooperating with the DOJ. On April 22, 2019, the Company was served with a putative class action lawsuit, Kawa Orthodontics LLP, et al. v. Laboratory Corporation of America Holdings, et al. , filed in the U.S. District Court for the Middle District of Florida. The lawsuit alleges that on or about February 6, 2019, the defendants violated the U.S. Telephone Consumer Protection Act (TCPA) by sending unsolicited facsimiles to Plaintiff and at least 40 other recipients without the recipients' prior express invitation or permission. The lawsuit seeks the greater of actual damages or the sum of $0.0005 for each violation, subject to trebling under the TCPA, and injunctive relief. The Company filed a motion to dismiss the case on May 28, 2019. In response to the Motion to Dismiss, the Plaintiff filed an amended complaint, which contains additional allegations, including allegations related to another facsimile. On December 16, 2019, the Plaintiff filed a notice withdrawing its Motion for Class Certification and all class allegations in the Amended Complaint. In January 2020, the parties settled the lawsuit. On May 14, 2019, Retrieval-Masters Creditors Bureau, Inc. d/b/a American Medical Collection Agency (AMCA), an external collection agency, notified the Company about a security incident AMCA experienced that may have involved certain personal information about some of the Company’s patients (the AMCA Incident). The Company referred patient balances to AMCA only when direct collection efforts were unsuccessful. The Company’s systems were not impacted by the AMCA Incident. Upon learning of the AMCA Incident, the Company promptly stopped sending new collection requests to AMCA and stopped AMCA from continuing to work on any pending collection requests from the Company. AMCA informed the Company that it appeared that an unauthorized user had access to AMCA’s system between August 1, 2018 and March 30, 2019, and that AMCA could not rule out the possibility that personal information on AMCA’s system was at risk during that time period. Information on AMCA’s affected system from the Company may have included name, address, and balance information for the patient and person responsible for payment, along with the patient’s phone number, date of birth, referring physician, and date of service. The Company was later informed by AMCA that health insurance information may have been included for some individuals, and because some insurance carriers utilize the Social Security Number as a subscriber identification number, the Social Security Number for some individuals may also have been affected. No ordered tests, laboratory test results, or diagnostic information from the Company were in the AMCA affected system. The Company notified individuals for whom it had a valid mailing address. For the individuals whose Social Security Number was affected, the notice included an offer to enroll in credit monitoring and identity protection services that will be provided free of charge for 24 months. Twenty-three putative class action lawsuits were filed against the Company related to the AMCA Incident in various U.S. District Courts. Numerous similar lawsuits have been filed against other health care providers who used AMCA. These lawsuits have been consolidated into a multidistrict litigation in the District of New Jersey. On November 15, 2019, the Plaintiffs filed a Consolidated Class Action Complaint in the U.S. District Court of New Jersey. On January 22, 2020, the Company filed Motions to Dismiss all claims. The consolidated Complaint generally alleges that the Company did not adequately protect its patients’ data and failed to timely notify those patients of the AMCA Incident. The Complaint asserts various causes of action, including but not limited to negligence, breach of implied contract, unjust enrichment, and the violation of state data protection statutes. The Complaint seeks damages on behalf of a class of all affected Company customers. The Company will vigorously defend the multi-district litigation. The Company was served with a shareholder derivative lawsuit, Raymond Eugenio, Derivatively on Behalf of Nominal Defendant, Laboratory Corporation of America Holdings v. Lance Berberian, et al. , filed in the Court of Chancery of the State of Delaware on April 23, 2020. The complaint asserts derivative claims on the Company’s behalf against the Company’s board of directors and certain executive officers. The complaint generally alleges that the defendants failed to ensure that the Company utilized proper cybersecurity safeguards and failed to implement a sufficient response to data security incidents, including the AMCA Incident. The complaint asserts derivative claims for breach of fiduciary duty and seeks relief including damages, certain disclosures, and certain changes to the Company’s internal governance practices. The lawsuit will be vigorously defended. Certain governmental entities have requested information from the Company related to the AMCA Incident. The Company received a request for information from the Office for Civil Rights (OCR) of the Department of Health and Human Services. On April 28, 2020, OCR notified the Company of the closure of its inquiry. The Company has also received requests from a mutil-state group of state Attorneys General and is cooperating with these requests for information. Three putative class action lawsuits related to California wage and hour laws have been served on the Company. On September 21, 2018, the Company was served with a putative class action lawsuit, Alma Haro v. Laboratory Corporation of America, et al ., filed in the Superior Court of California, County of Los Angeles. On June 10, 2019, the Company was served with a putative class action lawsuit, Ignacio v. Laboratory Corporation of America , filed in Superior Court of California, County of Los Angeles. On July 1, 2019, the Company was served with a putative class action lawsuit, Jan v. Laboratory Corporation of America , filed in the Superior Court of California, County of Sacramento. All three cases were subsequently removed to the U.S. District Court for the Central District of California, and then consolidated for all pre-trial proceedings. In the lawsuits, Plaintiffs allege that employees were not properly paid overtime compensation, minimum wages, meal and rest break premiums, did not receive compliant wage statements, and were not properly paid wages upon termination of employment. The Plaintiffs assert these actions violate various California Labor Code provisions and constitute an unfair competition practice under California law. The lawsuits seek monetary damages, civil penalties, and recovery of attorney's fees and costs. The Company will vigorously defend the lawsuits. On July 30, 2019, the Company was served with a class action lawsuit, Mitchell v. Covance, Inc. et al. , filed in the U.S. District Court for the Eastern District of Pennsylvania. Plaintiff alleges that certain individuals employed by Covance Inc. and Chiltern International Inc. were misclassified as exempt employees under the Fair Labor Standards Act and the Pennsylvania Minimum Wage Act and were thereby not properly paid overtime compensation. The lawsuit seeks monetary damages, liquidated damages, and recovery of attorneys’ fees and costs. On February 3, 2020, the Court denied without prejudice the Plaintiff's motion to conditionally certify a putative class action. The Company will vigorously defend the lawsuit. On January 31, 2020, the Company was served with a putative class action lawsuit, Luke Davis and Julian Vargas, et al. v. Laboratory Corporation of America Holdings , filed in the U.S. District Court for the Central District of California. The lawsuit alleges that visually impaired patients are unable to use the Company's touchscreen kiosks at Company patient service centers in violation of the Americans with Disabilities Act and similar California statutes. The lawsuit seeks statutory damages, injunctive relief, and attorney's fees and costs. The Company will vigorously defend the lawsuit. On April 20, 2020, a former employee filed a putative class action lawsuit, Jose Bermejo v. Laboratory Corporation of America in the Superior Court of California, County of Los Angeles Central District, alleging that certain non-exempt California-based employees were not properly compensated for driving time or properly paid wages upon termination of employment. The Plaintiff asserts these actions violate various California Labor Code provisions and Section 17200 of the Business and Professional Code. The lawsuit seeks monetary damages, civil penalties, and recovery of attorney’s fees and costs. The Company will vigorously defend the lawsuit. Under the Company's present insurance programs, coverage is obtained for catastrophic exposure as well as those risks required to be insured by law or contract. The Company is responsible for the uninsured portion of losses related primarily to general, professional and vehicle liability, certain medical costs and workers' compensation. The self-insured retentions are on a per-occurrence basis without any aggregate annual limit. Provisions for losses expected under these programs are recorded based upon the Company's estimates of the aggregated liability of claims incurred.

PENSION AND POSTRETIREMENT PLAN

PENSION AND POSTRETIREMENT PLANS	3 Months Ended
	Mar. 31, 2020
Postemployment Benefits [Abstract]
Pension And Postretirement Plans	PENSION AND POSTRETIREMENT PLANS Retirement Plans All employees eligible for the LCD defined-contribution retirement plan (LCD 401K Plan) receive a minimum 3% non-elective contribution (NEC) concurrent with each payroll period. Employees are not required to make a contribution to the LCD 401K Plan to receive the NEC. The NEC is non-forfeitable and vests immediately. The LCD 401K Plan also permits discretionary contributions by the Company of 1% to 3% of pay for eligible employees based on service. For the three months ended March 31, 2020 , and 2019 , total expense for the LCD 401K Plan was $13.5 and $16.0 , respectively. All of the CDD U.S. employees are eligible to participate in the CDD 401K Plan, which is available on a voluntary basis and features a maximum 4.5% Company match, based upon a percentage of the employee’s contributions. The Company incurred expense of $23.4 and $19.9 for the Covance 401K plan during the three months ended March 31, 2020 , and 2019 , respectively. The Company also maintains several other small 401K plans associated with companies acquired over the last several years. Pension Plans The Company has a defined-benefit retirement plan (Company Plan) and a nonqualified supplemental retirement plan (PEP). Both plans have been closed to new participants since December 31, 2009. Employees participating in the Company Plan and PEP no longer earn service-based credits, but continue to earn investment credits. The Company Plan covers substantially all employees employed prior to December 31, 2009. The benefits to be paid under the Company Plan are based on years of credited service through December 31, 2009, interest credits and average compensation. The Company's policy is to fund the Company Plan with at least the minimum amount required by applicable regulations. The PEP covers a portion of the Company's senior management group. Prior to 2010, the PEP provided for the payment of the difference, if any, between the amount of any maximum limitation on annual benefit payments under the Employee Retirement Income Security Act of 1974 and the annual benefit that would be payable under the Company Plan but for such limitation. Effective January 1, 2010, employees participating in the PEP no longer earn service-based credits. The PEP is an unfunded plan. The effect on operations for the Company Plan and the PEP is summarized as follows: Three Months Ended March 31, 2020 2019 Service cost for administrative expenses $ 1.3 $ 1.0 Interest cost on benefit obligation 2.8 3.5 Expected return on plan assets (3.7 ) (3.8 ) Net amortization and deferral 2.6 2.6 Defined benefit plan costs $ 3.0 $ 3.3 The service cost component of net periodic pension cost and net periodic post-retirement benefit cost is included in operating expenses with other employee compensation costs. The other components of net benefit cost, including amortization or prior service cost/credit and settlement and curtailment effects are included in other, net non-operating expenses. During the three months ended March 31, 2020 , the Company made no contributions to the Company Plan. The related net pension obligation for the Company Plan and PEP was $93.1 and $93.4 as of March 31, 2020 and December 31, 2019 , respectively. As a result of the Covance acquisition, the Company sponsors two defined benefit pension plans for the benefit of its employees at two U.K. subsidiaries (U.K. Plans) and one defined benefit pension plan for the benefit of its employees at a German subsidiary (German Plan), all of which are legacy plans of previously acquired companies. The U.K. Plans were closed to future accrual as of December 31, 2019. Benefit amounts for all three plans are based upon years of service and compensation; however, the U.K. Plans were based on service and compensation through December 31, 2019. The German Plan is unfunded while the U.K. Plans are funded. The Company’s funding policy has been to contribute annually a fixed percentage of the eligible employee's salary, and additional amounts, at least equal to the local statutory funding requirements. As a result of the Envigo acquisition, the Company assumed a defined benefit pension plan for the benefit of Envigo's U.K. employees (the Envigo Plan), which is a legacy plan of a company previously acquired by Envigo. The Envigo Plan is a funded plan that is closed to future accrual. The Company’s funding policy has been to contribute amounts at least equal to the local statutory funding requirements. The related net pension obligation for these plans inclusive of the U.K. Plans, German Plan, and the Envigo Plan, was $88.6 and $99.1 as of March 31, 2020 and December 31, 2019 , respectively.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The Company’s population of financial assets and liabilities subject to fair value measurements as of March 31, 2020 , and December 31, 2019 , is as follows: Fair Value Measurements as of Fair Value as of March 31, 2020 Balance Sheet Using Fair Value Hierarchy Classification March 31, 2020 Level 1 Level 2 Level 3 Noncontrolling interest put Noncontrolling interest $ 14.6 $ — $ 14.6 $ — Cross currency swaps Other assets, net 23.1 — 23.1 — Interest rate swaps Other assets, net 3.3 — 3.3 — Cash surrender value of life insurance policies Other assets, net 68.0 — 68.0 — Deferred compensation liability Other liabilities 66.7 — 66.7 — Contingent consideration Other liabilities 6.4 — — 6.4 Fair Value Measurements as of Fair Value as of December 31, 2019 Balance Sheet Using Fair Value Hierarchy Classification December 31, 2019 Level 1 Level 2 Level 3 Noncontrolling interest put Noncontrolling interest $ 15.8 $ — $ 15.8 $ — Cross currency swaps Other assets, net 3.2 — 3.2 — Interest rate swaps Other assets, net 1.5 — 1.5 — Cash surrender value of life insurance policies Other assets, net 80.2 — 80.2 — Deferred compensation liability Other liabilities 76.7 — 76.7 — Investment in equity securities Other current assets 9.1 9.1 — — Contingent consideration Other liabilities 9.9 — — 9.9 Fair Value Measurement of Level 3 Liabilities Contingent Consideration Balance at December 31, 2019 $ 9.9 Payments (1.4 ) Adjustments (2.1 ) Balance at March 31, 2020 $ 6.4 The Company has a noncontrolling interest put related to its Ontario subsidiary that has been classified as mezzanine equity in the Company’s condensed consolidated balance sheets. The noncontrolling interest put is valued at its contractually determined value, which approximates fair value. The Company offers certain employees the opportunity to participate in an employee-funded deferred compensation plan (DCP). A participant's deferrals are allocated by the participant to one or more of 16 measurement funds, which are indexed to externally managed funds. From time to time, to offset the cost of the growth in the participant's investment accounts, the Company purchases life insurance policies, with the Company named as beneficiary of the policies. Changes in the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying investments, which are typically invested in a similar manner to the participants' allocations. Changes in the fair value of the DCP obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. The cash surrender value and the DCP obligations are classified within Level 2 because their inputs are derived principally from observable market data by correlation to the hypothetical investments. Contingent acquisition consideration liabilities are measured at fair value using Level 3 valuations. These contingent consideration liabilities were recorded at fair value on the acquisition date and are remeasured quarterly based on the then assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration payable can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measure is based on significant inputs that are not observable in the market, they are categorized as Level 3. The carrying amounts of cash and cash equivalents, accounts receivable, income taxes receivable, and accounts payable are considered to be representative of their respective fair values due to their short-term nature. The fair market value of the Senior Notes, based on market pricing, was approximately $6,007.2 and $6,140.6 as of March 31, 2020 , and December 31, 2019

DERIVATIVE INSTRUMENTS AND HEDG

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	3 Months Ended
	Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments, Gain (Loss) [Table Text Block]	The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value hedging relationships: Amount of pre-tax gain/(loss) included in other comprehensive income Amounts reclassified to the Statement of Operations Three Months Ended March 31, Three Months Ended March 31, 2020 2019 2020 2019 Interest rate swap contracts $ 1.8 $ 2.5 $ — $ — Cross currency swaps $ 19.9 $ 11.5 $ — $ —
Derivative Instruments And Hedging Activities	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES The Company addresses its exposure to market risks, principally the market risk associated with changes in interest rates and foreign currency exchange rates, through a controlled program of risk management that includes, from time to time, the use of derivative financial instruments. The Company does not hold or issue derivative financial instruments for trading purposes. The Company does not believe that its exposure to market risk is material to the Company’s financial position or results of operations. Interest Rate Swap The Company is party to a fixed-to-variable interest rate swap agreement for its 4.625% senior notes due 2020 with a notional amount of $300.0 and variable interest rates based on one-month LIBOR plus 2.298% to hedge against changes in the fair value of a portion of the Company's long term debt. This derivative financial instrument is accounted for as fair value hedge of the Senior Notes due 2020. These interest rate swaps are included in other long-term assets or liabilities, as applicable, and added to the value of the Senior Notes. As the specific terms and notional amount of the derivative financial instrument matches those of the fixed-rate debt being hedged, the derivative instrument is assumed to be a perfectly effective hedge and accordingly, there is no impact to the Company's Condensed Consolidated Statements of Operations. Cash flows from the interest rate swap are included in operating activities. Carrying amount of hedged liabilities as of Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liabilities as of March 31, 2020 December 31, 2019 March 31, 2020 December 31, 2019 Balance Sheet Line Item in which Hedged Items are Included Current portion, long term debt $ 303.3 $ 301.5 $ 3.3 $ 1.5 Cross Currency Swap During the fourth quarter of 2018, the Company entered into six U.S. Dollar to Swiss Franc cross-currency swap agreements with an aggregate notional value of $600.0 and which are accounted for as a hedge against the impact of foreign exchange movements on its net investment in a Swiss subsidiary. Of the notional value, $300.0 matures in 2022 and $300.0 matures in 2025. These cross currency swaps maturing in 2022 and 2025 are included in other long-term assets as of March 31, 2020 . Changes in the fair value of the cross-currency swaps are recorded as a component of the foreign currency translation adjustment in accumulated other comprehensive income in the Condensed Consolidated Balance Sheet until the hedged item is recognized in earnings. The cumulative amount of the fair value hedging adjustment included in the current value of the cross currency swaps is $19.9 for the three months ended March 31, 2020 , and was recognized as currency translation within the Condensed Consolidated Statement of Comprehensive Earnings. There were no amounts reclassified from the Condensed Consolidated Statement of Comprehensive Earnings to the Condensed Consolidated Statement of Operations during the three months ended March 31, 2020 . The table below presents the fair value of derivatives on a gross basis and the balance sheet classification of those instruments: March 31, 2020 December 31, 2019 Fair Value of Derivative Fair Value of Derivative Balance Sheet Caption Asset Liability U.S. Dollar Notional Asset Liability U.S. Dollar Notional Derivatives Designated as Hedging Instruments Interest rate swap Prepaid expenses and other/Other liabilities $ 3.3 $ — $ 300.0 $ 1.5 $ — $ 300.0 Cross currency swaps Other assets, net or Other liabilities $ 23.1 $ — $ 600.0 $ 3.2 $ — $ 600.0 The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value hedging relationships: Amount of pre-tax gain/(loss) included in other comprehensive income Amounts reclassified to the Statement of Operations Three Months Ended March 31, Three Months Ended March 31, 2020 2019 2020 2019 Interest rate swap contracts $ 1.8 $ 2.5 $ — $ — Cross currency swaps $ 19.9 $ 11.5 $ — $ — No gains or losses from derivative instruments classified as hedging instruments have been recognized into income for the three and three months ended March 31, 2020 and 2019.
Schedule of Derivative Instruments [Table Text Block]	The table below presents the fair value of derivatives on a gross basis and the balance sheet classification of those instruments: March 31, 2020 December 31, 2019 Fair Value of Derivative Fair Value of Derivative Balance Sheet Caption Asset Liability U.S. Dollar Notional Asset Liability U.S. Dollar Notional Derivatives Designated as Hedging Instruments Interest rate swap Prepaid expenses and other/Other liabilities $ 3.3 $ — $ 300.0 $ 1.5 $ — $ 300.0 Cross currency swaps Other assets, net or Other liabilities $ 23.1 $ — $ 600.0 $ 3.2 $ — $ 600.0

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	3 Months Ended
	Mar. 31, 2020
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information	Three Months Ended March 31, 2020 2019 Supplemental schedule of cash flow information: Cash paid during period for: Interest $ 80.0 $ 99.7 Income taxes, net of refunds 5.8 (2.2 ) Disclosure of non-cash financing and investing activities: Conversion of zero-coupon convertible debt — 7.3 Change in accrued property, plant and equipment (14.0 ) (12.1 )
Supplemental Cash Flow Information	SUPPLEMENTAL CASH FLOW INFORMATION Three Months Ended March 31, 2020 2019 Supplemental schedule of cash flow information: Cash paid during period for: Interest $ 80.0 $ 99.7 Income taxes, net of refunds 5.8 (2.2 ) Disclosure of non-cash financing and investing activities: Conversion of zero-coupon convertible debt — 7.3 Change in accrued property, plant and equipment (14.0 ) (12.1 )

BUSINESS ACQUISITIONS

BUSINESS ACQUISITIONS	3 Months Ended
	Mar. 31, 2020
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	BUSINESS ACQUISITIONS AND DISPOSITIONS On June 3, 2019 , CDD acquired Envigo's nonclinical contract research services business, expanding CDD's global nonclinical drug development capabilities with additional locations and resources. Additionally, the Company divested the Covance Research Products (CRP) business, which was a part of CDD, to Envigo. As part of this sale, CDD entered into a multi-year, renewable supply agreement with Envigo. The Company paid cash consideration of $601.0 , received a floating rate secured note of $110.0 , and recorded a loss on the sale of CRP of $12.2 . The Company funded the transaction through a new term loan facility. The preliminary valuation of acquired assets and assumed liabilities in the transaction as of June 3, 2019, include the following: Consideration Transferred Cash consideration $ 601.0 Fair value of CRP 110.0 Total $ 711.0 Preliminary June 30, 2019 Measurement Period Adjustments Preliminary March 31, 2020 Net Assets Acquired Cash and cash equivalents $ 15.1 $ (3.7 ) $ 11.4 Accounts receivable 16.5 (4.6 ) 11.9 Unbilled services 26.5 (0.3 ) 26.2 Inventories 4.5 — 4.5 Prepaid expenses and other 3.5 6.3 9.8 Property, plant and equipment (including ROU operating lease assets) 99.1 25.8 124.9 Deferred income taxes 25.5 (11.5 ) 14.0 Goodwill 432.2 (51.4 ) 380.8 Customer relationships 125.8 15.0 140.8 Trade name and trademarks 0.6 — 0.6 Other assets 9.9 — 9.9 Total assets acquired 759.2 (24.4 ) 734.8 Accounts payable 15.4 (0.2 ) 15.2 Accrued expenses and other 11.6 (1.5 ) 10.1 Unearned revenue 49.9 — 49.9 Operating lease liabilities 15.0 (15.0 ) — Other liabilities 66.3 (7.7 ) 58.6 Total liabilities acquired 158.2 (24.4 ) 133.8 Net Envigo assets acquired 601.0 $ — $ 601.0 Floating rate secured note receivable due 2022 110.0 Total $ 711.0 The preliminary purchase consideration for Envigo has been allocated to the estimated fair market value of the net assets acquired, including approximately $141.4 in identifiable intangible assets and a residual amount of non-tax-deductible goodwill of approximately $380.8 . The amortization period for intangible assets acquired is 11 years for customer relationships. The purchase price allocation for the Envigo transaction is still preliminary and subject to change. The areas of the purchase price allocation that are not yet finalized relate primarily to goodwill and the impact of finalizing deferred taxes. Accordingly, adjustments may be made as additional information is obtained about the facts and circumstances that existed as of the valuation date. The Company expects these purchase price allocations to be finalized by the second quarter of 2020. Any adjustments will be recorded in the period in which they are identified. During the three months ended March 31, 2020, the Company recorded a $5.0 charge for the estimated credit loss related to the CDD floating rate secured note receivable due 2022 from Envigo. During the three months ended March 31, 2019, the Company acquired various businesses and related assets for approximately $47.3 in cash (net of cash acquired). The purchase consideration for all acquisitions in that period has been allocated to the estimated fair market value of the net assets acquired, including approximately $24.8 in identifiable intangible assets and a residual amount of goodwill of approximately $22.1 . These acquisitions were made primarily to extend the Company's geographic reach in important market areas, enhance the Company's scientific differentiation and to expand the breadth and scope of the Company's CRO services. Unaudited Pro Forma Information Had the Company's total 2019 acquisitions been completed as of January 1, 2019, the Company's pro forma results would have been as follows: Three Months Ended March 31, 2019 Revenues $ 2,832.6 Net earnings attributable to Laboratory Corporation of America Holdings $ 188.0

BUSINESS SEGMENT INFORMATION Bu

BUSINESS SEGMENT INFORMATION Business Segment information (Notes)	3 Months Ended
	Mar. 31, 2020
Segment Reporting Information [Line Items]
Segment Reporting Disclosure [Text Block]	BUSINESS SEGMENT INFORMATION The following table is a summary of segment information for the three months ended March 31, 2020 , and 2019 . The management approach has been used to present the following segment information. This approach is based upon the way the management of the Company organizes segments within an enterprise for making operating decisions and assessing performance. Financial information is reported on the basis that it is used internally by the chief operating decision maker (CODM) for evaluating segment performance and deciding how to allocate resources to segments. The Company’s chief executive officer has been identified as the CODM. Segment asset information is not presented because it is not used by the CODM at the segment level. Operating earnings of each segment represents revenues less directly identifiable expenses to arrive at operating income for the segment. General management and administrative corporate expenses are included in general corporate expenses below. Three Months Ended March 31, 2020 2019 Revenues: LCD $ 1,702.0 $ 1,722.0 CDD 1,143.8 1,074.7 Intercompany eliminations and other (22.0 ) (5.5 ) Revenues 2,823.8 2,791.2 Operating earnings (loss): LCD 188.4 268.3 CDD (338.7 ) 88.0 General corporate expenses (42.3 ) (38.1 ) Total operating income (loss) (192.6 ) 318.2 Non-operating expenses, net (75.1 ) (63.5 ) Earnings (loss) before income taxes (267.7 ) 254.7 Provision for income taxes 49.2 68.8 Net earnings (loss) (316.9 ) 185.9 Less net income attributable to noncontrolling interests (0.3 ) (0.3 ) Net income (loss) attributable to Laboratory Corporation of America Holdings $ (317.2 ) $ 185.6

BASIS OF FINANCIAL STATEMENT _2

BASIS OF FINANCIAL STATEMENT PRESENTATION Use of Estimates (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The extent to which the COVID-19 pandemic impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of March 31, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s implicit price concessions and credit losses, equity investments, software, notes receivable and the carrying value of goodwill and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods.

BASIS OF FINANCIAL STATEMENT _3

BASIS OF FINANCIAL STATEMENT PRESENTATION New Accounting Pronouncements (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	New Accounting Pronouncements In August 2018, the FASB issued a new accounting standard to reduce, modify, and add to the disclosure requirements on defined benefit pension and other postretirement plans. The standard is effective on January 1, 2021, with early adoption permitted. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements. In December 2019, the FASB issued a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective January 1, 2021, with early adoption permitted. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements. In January 2020, the FASB issued a new accounting standard to clarify the interaction of the accounting for equity securities and investments accounted for under the equity method of accounting and the accounting for certain forward contracts and purchased options. The standard is effective January 1, 2021. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements. In March 2020, the FASB issued a new accounting standard to provide optional expedients and exceptions if certain conditions are met for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The expedients and exceptions in the standard are effective between March 12, 2020 and December 31, 2022. The Company did not elect to apply any of the expedients or exceptions for the period ended March 31, 2020 and is currently evaluating the impact this new standard will have on the consolidated financial statements.

BASIS OF FINANCIAL STATEMENT _4

BASIS OF FINANCIAL STATEMENT PRESENTATION Novel Coronavirus (COVID-19) Financial Statement Impact (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Novel Coranvirus (Covid-19) Financial Statement Impact [Policy Text Block]	Novel Coronavirus (COVID-19) Financial Statement Impact In March 2020, the novel strain of coronavirus, now known as COVID-19, was declared a pandemic. The COVID-19 pandemic has and continues to have an extensive impact on the global health and economic environments. By mid-March 2020, government restrictions, social distancing guidelines, and overall customer caution associated with the COVID-19 pandemic negatively affected LCD’s revenues and CDD's operations. For LCD, reduction in demand impacted testing volumes broadly but was more heavily weighted towards routine tests. This reduction in demand impacted testing volumes broadly but was more heavily weighted towards routine tests. The performance of CDD has also been negatively affected by the COVID-19 pandemic through numerous study site closures around the world as well as customer initiated delays for new patient recruitment for existing clinical trials and start-up of new clinical trials. As a result of the impact of the COVID-19 pandemic, during the three months ended March 31, 2020 , the Company recorded goodwill and other asset impairment charges of $437.4 : $426.4 within CDD and $11.0 within LCD. See Note 6 Goodwill and Intangible Assets for discussion of goodwill and intangible asset impairment and Note 2 Revenue for the discussion of credit losses and additional price concessions. The Company also wrote-off or wrote down certain of the Company's investments by $ 20.2 due to the impact of COVID-19, $ 7.1 included in Equity method earnings (loss), net and $13.1 included in Other, net.

BASIS OF FINANCIAL STATEMENT _5

BASIS OF FINANCIAL STATEMENT PRESENTATION Recently Adopted Accounting Standards (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Recently Adopted Accounting Guidance [Policy Text Block]	Recently Adopted Guidance In June 2016, the FASB issued a new accounting standard intended to provide financial statement users with more decision-useful information about expected credit losses and other commitments to extend credit held by the reporting entity. The standard replaces the incurred loss impairment methodology in current generally accepted accounting principles (GAAP) with one that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company recorded an opening retained earnings adjustment of $7.0 with the adoption of this standard on January 1, 2020. In August 2018, the FASB issued a new accounting standard to reduce, modify, and add to the disclosure requirements on fair value measurements. The Company adopted this standard effective January 1, 2020. The adoption of this standard did not have a material impact on the consolidated financial statements. In August 2018, the FASB issued a new accounting standard to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted this standard effective January 1, 2020. The adoption of this standard did not have a material impact on the consolidated financial statements.

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Reconciliation of Basic earnings per Share to Diluted Earnings per Share	The following represents a reconciliation of basic earnings (loss) per share to diluted earnings (loss) per share: Three Months Ended March 31, 2020 2019 Earnings (Loss) Shares Per Share Amount Earnings Shares Per Share Amount Basic earnings (loss) per share: Net earnings (loss) $ (317.2 ) 97.2 $ (3.27 ) $ 185.6 98.6 $ 1.88 Dilutive effect of employee stock options and awards — — — 0.9 Net earnings (loss) including impact of dilutive adjustments (a) $ (317.2 ) 97.2 $ (3.27 ) $ 185.6 99.5 $ 1.86
Potential common shares not included in computation of diluted earnings per share	The following table summarizes the potential common shares not included in the computation of diluted earnings per share because their impact would have been antidilutive: Three Months Ended March 31, 2020 2019 Employee stock options and awards 1.3 0.3

RESTRUCTURING AND OTHER SPECI_2

RESTRUCTURING AND OTHER SPECIAL CHARGES Restructuring and Other Special Charges Detail (Tables)	3 Months Ended
	Mar. 31, 2020
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following represents the Company’s restructuring reserve activities for the period indicated: LCD CDD Severance and Other Employee Costs Facility Costs Severance and Other Employee Costs Facility Costs Total Balance as of December 31, 2019 $ 0.5 $ 2.7 $ 5.5 $ 4.7 $ 13.4 Restructuring charges 2.1 1.5 2.5 2.7 8.8 Adjustments to prior restructuring accruals (0.1 ) (0.2 ) 0.6 — 0.3 Impairment of lab facility — — — 4.7 4.7 Impairment of operating lease right-of-use asset — 4.8 — 6.8 11.6 Cash payments and other adjustments (0.3 ) (8.7 ) (4.4 ) (12.2 ) (25.6 ) Balance as of March 31, 2020 $ 2.2 $ 0.1 $ 4.2 $ 6.7 $ 13.2 Current $ 7.8 Non-current 5.4 $ 13.2

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the nine months ended March 31, 2020 , are as follows: LCD CDD Total Balance as of January 1, 2020 $ 3,721.5 $ 4,143.5 $ 7,865.0 Impairment (3.7 ) (418.7 ) (422.4 ) Foreign currency impact and other adjustments to goodwill (6.6 ) (47.5 ) (54.1 ) Balance as of March 31, 2020 $ 3,711.2 $ 3,677.3 $ 7,388.5
Schedule of Intangible Assets and Goodwill [Table Text Block]	The components of identifiable intangible assets are as follows: March 31, 2020 December 31, 2019 Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Customer relationships $ 4,414.4 $ (1,371.0 ) $ 3,043.4 $ 4,441.7 $ (1,329.5 ) $ 3,112.2 Patents, licenses and technology 444.4 (238.7 ) 205.7 453.6 (235.7 ) 217.9 Non-compete agreements 90.7 (62.3 ) 28.4 90.9 (60.5 ) 30.4 Trade name 407.3 (228.8 ) 178.5 408.2 (219.9 ) 188.3 Land use right 10.8 (5.8 ) 5.0 10.9 (5.5 ) 5.4 Canadian licenses 444.1 — 444.1 480.3 — 480.3 $ 5,811.7 $ (1,906.6 ) $ 3,905.1 $ 5,885.6 $ (1,851.1 ) $ 4,034.5

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Company's population of financial assets and liabilities subject to fair value measurements	The Company’s population of financial assets and liabilities subject to fair value measurements as of March 31, 2020 , and December 31, 2019 , is as follows: Fair Value Measurements as of Fair Value as of March 31, 2020 Balance Sheet Using Fair Value Hierarchy Classification March 31, 2020 Level 1 Level 2 Level 3 Noncontrolling interest put Noncontrolling interest $ 14.6 $ — $ 14.6 $ — Cross currency swaps Other assets, net 23.1 — 23.1 — Interest rate swaps Other assets, net 3.3 — 3.3 — Cash surrender value of life insurance policies Other assets, net 68.0 — 68.0 — Deferred compensation liability Other liabilities 66.7 — 66.7 — Contingent consideration Other liabilities 6.4 — — 6.4 Fair Value Measurements as of Fair Value as of December 31, 2019 Balance Sheet Using Fair Value Hierarchy Classification December 31, 2019 Level 1 Level 2 Level 3 Noncontrolling interest put Noncontrolling interest $ 15.8 $ — $ 15.8 $ — Cross currency swaps Other assets, net 3.2 — 3.2 — Interest rate swaps Other assets, net 1.5 — 1.5 — Cash surrender value of life insurance policies Other assets, net 80.2 — 80.2 — Deferred compensation liability Other liabilities 76.7 — 76.7 — Investment in equity securities Other current assets 9.1 9.1 — — Contingent consideration Other liabilities 9.9 — — 9.9
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Fair Value Measurement of Level 3 Liabilities Contingent Consideration Balance at December 31, 2019 $ 9.9 Payments (1.4 ) Adjustments (2.1 ) Balance at March 31, 2020 $ 6.4

SUPPLEMENTAL CASH FLOW INFORM_2

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2020
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information	Three Months Ended March 31, 2020 2019 Supplemental schedule of cash flow information: Cash paid during period for: Interest $ 80.0 $ 99.7 Income taxes, net of refunds 5.8 (2.2 ) Disclosure of non-cash financing and investing activities: Conversion of zero-coupon convertible debt — 7.3 Change in accrued property, plant and equipment (14.0 ) (12.1 )
Supplemental Cash Flow Information	SUPPLEMENTAL CASH FLOW INFORMATION Three Months Ended March 31, 2020 2019 Supplemental schedule of cash flow information: Cash paid during period for: Interest $ 80.0 $ 99.7 Income taxes, net of refunds 5.8 (2.2 ) Disclosure of non-cash financing and investing activities: Conversion of zero-coupon convertible debt — 7.3 Change in accrued property, plant and equipment (14.0 ) (12.1 )

BUSINESS ACQUISITIONS Business

BUSINESS ACQUISITIONS Business Acquisitions Tables (Tables)	3 Months Ended
	Mar. 31, 2020
Business Acquisition [Line Items]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The preliminary valuation of acquired assets and assumed liabilities in the transaction as of June 3, 2019, include the following: Consideration Transferred Cash consideration $ 601.0 Fair value of CRP 110.0 Total $ 711.0 Preliminary June 30, 2019 Measurement Period Adjustments Preliminary March 31, 2020 Net Assets Acquired Cash and cash equivalents $ 15.1 $ (3.7 ) $ 11.4 Accounts receivable 16.5 (4.6 ) 11.9 Unbilled services 26.5 (0.3 ) 26.2 Inventories 4.5 — 4.5 Prepaid expenses and other 3.5 6.3 9.8 Property, plant and equipment (including ROU operating lease assets) 99.1 25.8 124.9 Deferred income taxes 25.5 (11.5 ) 14.0 Goodwill 432.2 (51.4 ) 380.8 Customer relationships 125.8 15.0 140.8 Trade name and trademarks 0.6 — 0.6 Other assets 9.9 — 9.9 Total assets acquired 759.2 (24.4 ) 734.8 Accounts payable 15.4 (0.2 ) 15.2 Accrued expenses and other 11.6 (1.5 ) 10.1 Unearned revenue 49.9 — 49.9 Operating lease liabilities 15.0 (15.0 ) — Other liabilities 66.3 (7.7 ) 58.6 Total liabilities acquired 158.2 (24.4 ) 133.8 Net Envigo assets acquired 601.0 $ — $ 601.0 Floating rate secured note receivable due 2022 110.0 Total $ 711.0
Business Acquisition, Pro Forma Information [Table Text Block]	Unaudited Pro Forma Information Had the Company's total 2019 acquisitions been completed as of January 1, 2019, the Company's pro forma results would have been as follows: Three Months Ended March 31, 2019 Revenues $ 2,832.6 Net earnings attributable to Laboratory Corporation of America Holdings $ 188.0
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]	Carrying amount of hedged liabilities as of Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liabilities as of March 31, 2020 December 31, 2019 March 31, 2020 December 31, 2019 Balance Sheet Line Item in which Hedged Items are Included Current portion, long term debt $ 303.3 $ 301.5 $ 3.3 $ 1.5

BUSINESS SEGMENT INFORMATION (T

BUSINESS SEGMENT INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2020
Segment Reconciliation of Operating Income to Consolidated [Abstract]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Three Months Ended March 31, 2020 2019 Revenues: LCD $ 1,702.0 $ 1,722.0 CDD 1,143.8 1,074.7 Intercompany eliminations and other (22.0 ) (5.5 ) Revenues 2,823.8 2,791.2 Operating earnings (loss): LCD 188.4 268.3 CDD (338.7 ) 88.0 General corporate expenses (42.3 ) (38.1 ) Total operating income (loss) (192.6 ) 318.2 Non-operating expenses, net (75.1 ) (63.5 ) Earnings (loss) before income taxes (267.7 ) 254.7 Provision for income taxes 49.2 68.8 Net earnings (loss) (316.9 ) 185.9 Less net income attributable to noncontrolling interests (0.3 ) (0.3 ) Net income (loss) attributable to Laboratory Corporation of America Holdings $ (317.2 ) $ 185.6

REVENUE (Tables)

REVENUE (Tables)	3 Months Ended
	Mar. 31, 2020
Disaggregation of Revenue [Line Items]
Financing Receivable, Allowance for Credit Loss [Table Text Block]	The rollforward for the allowance for credit losses for the three months ended March 31, 2020 is as follows: For the Three Months Ended March 31, 2020 Accounts Receivable Unbilled Services Note Receivable Total Allowance for credit losses as of December 31, 2019 $ 19.0 $ 2.3 $ — $ 21.3 Current expected credit losses opening balance impact on retained earnings 1.8 0.2 5.0 7.0 Plus, credit loss expense 8.5 — 5.0 13.5 Less, write offs 0.4 0.1 — 0.5 Ending allowance for credit losses $ 28.9 $ 2.4 $ 10.0 $ 41.3
Contract with Customer, Asset and Liability [Table Text Block]	March 31, 2020 December 31, 2019 Receivables, which are included in accounts receivable $ 758.6 $ 771.1 Unbilled services 480.6 483.7 Unearned revenue 430.9 449.2
Revenue from Contract with Customer [Text Block]	REVENUES The Company's revenues by segment payers/customer groups for the three months ended March 31, 2020 , and 2019 , are as follows: For the Three Months Ended March 31, 2020 U.S. Canada United Kingdom Switzerland Other Europe Other Total Payer/Customer LCD Clients 16 % 1 % — % — % — % — % 17 % Patients 7 % — % — % — % — % — % 7 % Medicare and Medicaid 8 % — % — % — % — % — % 8 % Third-party 26 % 2 % — % — % — % — % 28 % Total LCD revenues by payer 57 % 3 % — % — % — % — % 60 % CDD Biopharmaceutical and medical 20 % — % 5 % 5 % 3 % 7 % 40 % Total revenues 77 % 3 % 5 % 5 % 3 % 7 % 100 % For the Three Months Ended March 31, 2019 U.S. Canada United Kingdom Switzerland Other Europe Other Total Payer/Customer LCD Clients 16 % 1 % — % — % — % — % 17 % Patients 8 % — % — % — % — % — % 8 % Medicare and Medicaid 9 % — % — % — % — % — % 9 % Third-party 26 % 2 % — % — % — % — % 28 % Total LCD revenues by payer 59 % 3 % — % — % — % — % 62 % CDD Biopharmaceutical and medical device companies 19 % — % 4 % 5 % 3 % 7 % 38 % Total revenues 78 % 3 % 4 % 5 % 3 % 7 % 100 % Contract costs CDD incurs sales commissions in the process of obtaining contracts with customers, which are recoverable through the service fees in the contract. Sales commissions that are payable upon contract award are recognized as assets and amortized over the expected contract term, along with related payroll tax expense. The amortization of commission expense is based on the weighted average contract duration for all commissionable awards in the respective business in which the commission expense is paid, which approximates the period over which goods and services are transferred to the customer. The amortization period of sales commissions ranges from approximately 12 to 57 months, depending on the business. For businesses that enter into primarily short-term contracts, the Company applies the practical expedient, which allows costs to obtain a contract to be expensed when incurred if the amortization period of the assets that would otherwise have been recognized is one year or less. Amortization of assets from sales commissions is included in selling, general, and administrative expense. CDD incurs costs to fulfill contracts with customers, which are recoverable through the service fees in the contract. Contract fulfillment costs include software implementation costs and setup costs for certain market access solutions. These costs are recognized as assets and amortized over the expected term of the contract to which the implementation relates, which is the period over which services are expected to be provided to the customer. This period typically ranges from 24 to 60 months. Amortization of deferred contract fulfillment costs is included in cost of goods sold. March 31, 2020 December 31, 2019 Sales commission assets $ 30.3 $ 28.6 Deferred contract fulfillment costs 13.8 14.9 Total $ 44.1 $ 43.5 Amortization related to sales commission assets and associated payroll taxes for the three months ended March 31, 2020 , and 2019 , was $5.3 and $4.5 , respectively. Amortization related to deferred contract fulfillment costs for the three months ended March 31, 2020 , and 2019 , was $3.0 and $1.8 , respectively. Receivables, Unbilled Services and Unearned Revenue Unbilled services are comprised primarily of unbilled receivables, but also include contract assets. A contract asset is recorded when a right to payment has been earned for work performed, but billing and payment for that work is determined by certain contractual milestones, whereas unbilled receivables are billable upon the passage of time. While CDD attempts to negotiate terms that provide for billing and payment of services prior or in close proximity to the provision of services, this is not always possible and there are fluctuations in the level of unbilled services and unearned revenue from period to period. The following table provides information about receivables, unbilled services, and unearned revenue (contract liabilities) from contracts with customers for CDD. March 31, 2020 December 31, 2019 Receivables, which are included in accounts receivable $ 758.6 $ 771.1 Unbilled services 480.6 483.7 Unearned revenue 430.9 449.2 Revenues recognized during the period, that were included in the unearned revenue balance at the beginning of the period for the three months ended March 31, 2020 and March 31, 2019 was $121.8 and $103.6 , respectively. Credit Loss Rollforward With the adoption of current expected credit loss standard in 2020, the Company estimates future expected losses on accounts receivable, unbilled services and notes receivable over the remaining collection period of the instrument. The rollforward for the allowance for credit losses for the three months ended March 31, 2020 is as follows: For the Three Months Ended March 31, 2020 Accounts Receivable Unbilled Services Note Receivable Total Allowance for credit losses as of December 31, 2019 $ 19.0 $ 2.3 $ — $ 21.3 Current expected credit losses opening balance impact on retained earnings 1.8 0.2 5.0 7.0 Plus, credit loss expense 8.5 — 5.0 13.5 Less, write offs 0.4 0.1 — 0.5 Ending allowance for credit losses $ 28.9 $ 2.4 $ 10.0 $ 41.3 The note receivable is the floating note receivable due 2022 from the Envigo transaction which is recorded in Other assets, net. During the three months ended, March 31, 2020, the Company also recorded $17.0 of additional implicit price concessions as a result of anticipated collection challenges from the economic decline. Performance Obligations Under Long-Term Contracts Long-term contracts at the Company consist primarily of fully managed clinical studies within CDD. The amount of existing performance obligations under such long-term contracts unsatisfied as of March 31, 2020 , was $4,494.9 . The Company expects to recognize approximately 35% of the remaining performance obligations as of March 31, 2020 as revenue over the next 12 months, and the balance thereafter. The Company's long-term contracts generally range from 1 to 8 years. Within CDD, revenues of $9.7 and $39.7 were recognized during the three months ended March 31, 2020 , and 2019 , respectively, from performance obligations that were satisfied in previous periods. This revenue comes from adjustments related to changes in scope and estimates in full service clinical studies.
Disaggregation of Revenue [Table Text Block]	The Company's revenues by segment payers/customer groups for the three months ended March 31, 2020 , and 2019 , are as follows: For the Three Months Ended March 31, 2020 U.S. Canada United Kingdom Switzerland Other Europe Other Total Payer/Customer LCD Clients 16 % 1 % — % — % — % — % 17 % Patients 7 % — % — % — % — % — % 7 % Medicare and Medicaid 8 % — % — % — % — % — % 8 % Third-party 26 % 2 % — % — % — % — % 28 % Total LCD revenues by payer 57 % 3 % — % — % — % — % 60 % CDD Biopharmaceutical and medical 20 % — % 5 % 5 % 3 % 7 % 40 % Total revenues 77 % 3 % 5 % 5 % 3 % 7 % 100 % For the Three Months Ended March 31, 2019 U.S. Canada United Kingdom Switzerland Other Europe Other Total Payer/Customer LCD Clients 16 % 1 % — % — % — % — % 17 % Patients 8 % — % — % — % — % — % 8 % Medicare and Medicaid 9 % — % — % — % — % — % 9 % Third-party 26 % 2 % — % — % — % — % 28 % Total LCD revenues by payer 59 % 3 % — % — % — % — % 62 % CDD Biopharmaceutical and medical device companies 19 % — % 4 % 5 % 3 % 7 % 38 % Total revenues 78 % 3 % 4 % 5 % 3 % 7 % 100 %
Capitalized Contract Cost [Table Text Block]	March 31, 2020 December 31, 2019 Sales commission assets $ 30.3 $ 28.6 Deferred contract fulfillment costs 13.8 14.9 Total $ 44.1 $ 43.5

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Supplemental Cash Flow Information	SUPPLEMENTAL CASH FLOW INFORMATION Three Months Ended March 31, 2020 2019 Supplemental schedule of cash flow information: Cash paid during period for: Interest $ 80.0 $ 99.7 Income taxes, net of refunds 5.8 (2.2 ) Disclosure of non-cash financing and investing activities: Conversion of zero-coupon convertible debt — 7.3 Change in accrued property, plant and equipment (14.0 ) (12.1 )

BASIS OF FINANCIAL STATEMENT _6

BASIS OF FINANCIAL STATEMENT PRESENTATION (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Accounts, Notes, Loans and Financing Receivable [Line Items]
Asset Impairment Charges	$ 437.4	$ 0
Revenues	2,823.8	2,791.2
Cost of Revenue	2,095.8	2,001.5
Contract with Customer, Liability	430.9		$ 449.2
Amortization of Deferred Sales Commissions	5.3	4.5
Assets, Current	2,891.1		2,981.2
Net Cash Provided by (Used in) Operating Activities	$ 203.8	$ 165.8
Percent of Revenue Contributed	100.00%	100.00%
Selling, general and administrative expenses	$ 395.5	$ 393.8
Nonoperating Income (Expense)	(75.1)	(63.5)
Provision for income taxes	49.2	68.8
Net earnings	(316.9)	185.9
Net Income (Loss) Attributable to Parent	$ (317.2)	$ 185.6
Basic earnings per common share (in dollars per share)	$ (3.27)	$ 1.88
Diluted earnings per common share (in dollars per share)	$ (3.27)	$ 1.86
Net Cash Provided by (Used in) Investing Activities	$ (106.6)	$ (140.5)
Net Cash Provided by (Used in) Financing Activities	(102.8)	(103.2)
Effect of exchange rate changes on cash and cash equivalents	(8.3)	(0.1)
Assets	17,298.4		18,046.4
Long-term debt, less current portion	2,458		2,655.8
Common stock, 92.8 and 93.5 shares outstanding at March 31, 2013 and December 31, 2012, respectively	18.5		20.1
Stockholders' Equity Attributable to Parent	7,020.1	7,111.3	7,567	$ 6,971.4
Liabilities and Equity	17,298.4		18,046.4
Capitalized Contract Cost, Amortization	3	1.8
Deferred Revenue, Revenue Recognized	121.8	103.6
Revenue, Remaining Performance Obligation, Amount	4,494.9
Contract with Customer, Performance Obligation Satisfied in Previous Period	9.7	39.7
Goodwill, Impairment Loss	422.4
Other than Temporary Impairment Losses, Investments	$ 20.2
Ownership percentage below which investments are generally accounted for on the cost method (in thousandths)	20.00%
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification			(7)
LabCorp Diagnostics [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Revenues	$ 1,702	$ 1,722
Percent of Revenue Contributed	60.00%	62.00%
Goodwill and Intangible Asset Impairment	$ 11
Goodwill, Impairment Loss	3.7
Covance Drug Development [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Revenues	$ 1,143.8	$ 1,074.7
Percent of Revenue Contributed	40.00%
Goodwill and Intangible Asset Impairment	$ 426.4
Goodwill, Impairment Loss	418.7
Equity Method Income (Loss), Net [Domain]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Other than Temporary Impairment Losses, Investments	7.1
Other Nonoperating Income (Expense) [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Other than Temporary Impairment Losses, Investments	13.1
Retained Earnings [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Net Income (Loss) Attributable to Parent	(317.2)	185.6
Stockholders' Equity Attributable to Parent	$ 7,529	$ 7,265.4	7,903.6	$ 7,079.8
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification			$ (7)

EARNINGS PER SHARE (Reconciliat

EARNINGS PER SHARE (Reconciliation of Basic Earnings Per Share to Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income [Abstract]
Net earnings attributable to Laboratory Corporation of America Holdings	$ (317.2)	$ 185.6
Shares [Abstract]
Net earnings, basic (in shares)	97.2	98.6
Dilutive effect of employee stock options and awards, (in shares)	0	0.9
Per Share Amount [Abstract]
Basic earnings per common share (in dollars per share)	$ (3.27)	$ 1.88
Diluted earnings per common share (in dollars per share)	$ (3.27)	$ 1.86
Net Income (Loss) Available to Common Stockholders, Diluted	$ (317.2)	$ 185.6
Weighted Average Number of Shares Outstanding, Diluted	97.2	99.5

EARNINGS PER SHARE (Potential c

EARNINGS PER SHARE (Potential common shares not included in computation of diluted earnings per share) (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Stock options (in shares)	1.3	0.3

RESTRUCTURING AND OTHER SPECI_3

RESTRUCTURING AND OTHER SPECIAL CHARGES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 13.2		$ 13.4
Restructuring Charges	8.8
Restructuring Reserve Settled With Cash And Other Adjustment	(25.6)
Net restructuring charges	25.4	$ 20.6
Restructuring charges related to severance and other employee costs	5.1	16.8
Other Asset Impairment Charges	4.7
Restructuring charges related to contractual obligations associated with leased facilities and other facility related costs	15.8	3.3
Employee Severance Benefits Related Restructuring Reserve Accrual Adjustment		(0.5)
Asset Impairment Charges	4.7
Operating Lease, Impairment Loss	11.6
Unused facility restructuring reserves	(0.2)
Reduction in total prior restructuring accruals	0.3
Restructuring Reserve, Current	7.8
Restructuring Reserve, Noncurrent	5.4
Covance Drug Development [Member]
Restructuring Cost and Reserve [Line Items]
Net restructuring charges	17.3	7.5
Covance Drug Development [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	4.2		5.5
Restructuring Charges	2.5
Restructuring Reserve Settled With Cash And Other Adjustment	(4.4)
Asset Impairment Charges	0
Operating Lease, Impairment Loss	0
Reduction in total prior restructuring accruals	(0.6)
Covance Drug Development [Member] | Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	6.7		4.7
Restructuring Charges	2.7
Restructuring Reserve Settled With Cash And Other Adjustment	(12.2)
Asset Impairment Charges	4.7
Operating Lease, Impairment Loss	6.8
Reduction in total prior restructuring accruals	0
LabCorp Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Net restructuring charges	8.1	$ 13.1
LabCorp Diagnostics [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	2.2		0.5
Restructuring Charges	2.1
Restructuring Reserve Settled With Cash And Other Adjustment	(0.3)
Asset Impairment Charges	0
Operating Lease, Impairment Loss	0
Reduction in total prior restructuring accruals	(0.1)
LabCorp Diagnostics [Member] | Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	0.1		$ 2.7
Restructuring Charges	1.5
Restructuring Reserve Settled With Cash And Other Adjustment	(8.7)
Asset Impairment Charges	0
Operating Lease, Impairment Loss	4.8
Reduction in total prior restructuring accruals	$ (0.2)

RESTRUCTURING RESERVES (Details

RESTRUCTURING RESERVES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020
Restructuring Cost and Reserve [Line Items]
Unused facility restructuring reserves	$ 0.2
Balance, beginning of period	13.4
Restructuring charges	8.8
Reduction of prior restructuring accruals	0.3
Cash payments and other adjustments	(25.6)
Balance, end of period	13.2
Current			$ 7.8
Non-current			5.4
Total Restructuring Reserve	13.2		13.2
Employee Severance Benefits Related Restructuring Reserve Accrual Adjustment		$ 0.5
LabCorp Diagnostics [Member] | Severance and Other Employee Costs [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning of period	0.5
Restructuring charges	2.1
Reduction of prior restructuring accruals	(0.1)
Cash payments and other adjustments	(0.3)
Balance, end of period	2.2
Total Restructuring Reserve	2.2		2.2
LabCorp Diagnostics [Member] | Lease and Other Facility Costs [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning of period	2.7
Restructuring charges	1.5
Reduction of prior restructuring accruals	(0.2)
Cash payments and other adjustments	(8.7)
Balance, end of period	0.1
Total Restructuring Reserve	0.1		0.1
Covance Drug Development [Member] | Severance and Other Employee Costs [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning of period	5.5
Restructuring charges	2.5
Reduction of prior restructuring accruals	(0.6)
Cash payments and other adjustments	(4.4)
Balance, end of period	4.2
Total Restructuring Reserve	4.2		4.2
Covance Drug Development [Member] | Lease and Other Facility Costs [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning of period	4.7
Restructuring charges	2.7
Reduction of prior restructuring accruals	0
Cash payments and other adjustments	(12.2)
Balance, end of period	6.7
Total Restructuring Reserve	$ 6.7		$ 6.7

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS (Changes in Carrying Amount of Goodwill) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Goodwill [Line Items]
Amortization of intangibles and other assets	$ 62,300,000	$ 57,100,000
Severance Costs	5,100,000	$ 16,800,000
Intangible Assets, Gross (Excluding Goodwill)	5,811,700,000		$ 5,885,600,000
Balance as of January 1	7,865,000,000
Adjustments to goodwill	(54,100,000)
Balance at end of period	7,388,500,000
Finite-Lived Intangible Assets, Accumulated Amortization	1,906,600,000		1,851,100,000
Intangible Assets, Net (Excluding Goodwill)	3,905,100,000		4,034,500,000
Goodwill, Impairment Loss	422,400,000
LabCorp Diagnostics [Member]
Goodwill [Line Items]
Goodwill and Intangible Asset Impairment	11,000,000
Balance as of January 1	3,721,500,000
Adjustments to goodwill	(6,600,000)
Balance at end of period	3,711,200,000
Goodwill, Impairment Loss	$ 3,700,000
Percentage Fair Value of Goodwill Exceeded Carrying Value	10.00%
Percentage Change in Discount Rate Used to Calculate Fair Value of Goodwill	1.00%
Value of Goodwill Impairment Following a Percentage Change in the Discount Rate Used to Calculate Goodwill for Reporting Unit	$ 40,000,000
Value of Reporting Units Goodwill Fair Value Exceeds Carrying Value	81.5
Covance Drug Development [Member]
Goodwill [Line Items]
Goodwill and Intangible Asset Impairment	426,400,000
Balance as of January 1	4,143,500,000
Adjustments to goodwill	(47,500,000)
Balance at end of period	3,677,300,000
Goodwill, Impairment Loss	$ 418,700,000
Percentage Fair Value of Goodwill Exceeded Carrying Value	10.00%
Percent Change in Discount Rate Used to Calculate Fair Value of Goodwill for Reporting Unit	1.00%
Percent of Fair Value Exceeding Carrying Value Post Percent Change in Discount Rate Used to Calculate Fair Value of Goodwill for Reporting Unit	2.00%
Value of Reporting Unit's Goodwill Following Impairment	$ 1,554,700,000
Value of Reporting Units Goodwill Fair Value Exceeds Carrying Value	631,900,000
Customer Relationships [Member]
Goodwill [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	4,414,400,000		4,441,700,000
Finite-Lived Intangible Assets, Accumulated Amortization	1,371,000,000		1,329,500,000
Intangible Assets, Net (Excluding Goodwill)	3,043,400,000		3,112,200,000
Patents, Licenses And Technology [Member]
Goodwill [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	444,400,000		453,600,000
Finite-Lived Intangible Assets, Accumulated Amortization	238,700,000		235,700,000
Intangible Assets, Net (Excluding Goodwill)	205,700,000		217,900,000
Noncompete Agreements [Member]
Goodwill [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	90,700,000		90,900,000
Finite-Lived Intangible Assets, Accumulated Amortization	62,300,000		60,500,000
Intangible Assets, Net (Excluding Goodwill)	28,400,000		30,400,000
Trade Names [Member]
Goodwill [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	407,300,000		408,200,000
Finite-Lived Intangible Assets, Accumulated Amortization	228,800,000		219,900,000
Intangible Assets, Net (Excluding Goodwill)	178,500,000		188,300,000
Use Rights [Member]
Goodwill [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	10,800,000		10,900,000
Finite-Lived Intangible Assets, Accumulated Amortization	5,800,000		5,500,000
Intangible Assets, Net (Excluding Goodwill)	5,000,000		5,400,000
Canadian licenses [Member]
Goodwill [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	444,100,000		480,300,000
Finite-Lived Intangible Assets, Accumulated Amortization	0		0
Intangible Assets, Net (Excluding Goodwill)	444,100,000		$ 480,300,000
Trade Names [Member] | Covance Drug Development [Member]
Goodwill [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)	$ 2,700,000

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS (Components of identifiable intangible assets) (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	$ 5,811.7	$ 5,885.6
Accumulated Amortization	(1,906.6)	(1,851.1)
Intangible Assets, Net (Excluding Goodwill)	3,905.1	4,034.5
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	4,414.4	4,441.7
Accumulated Amortization	(1,371)	(1,329.5)
Intangible Assets, Net (Excluding Goodwill)	3,043.4	3,112.2
Patents, Licenses And Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	444.4	453.6
Accumulated Amortization	(238.7)	(235.7)
Intangible Assets, Net (Excluding Goodwill)	205.7	217.9
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	90.7	90.9
Accumulated Amortization	(62.3)	(60.5)
Intangible Assets, Net (Excluding Goodwill)	28.4	30.4
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	407.3	408.2
Accumulated Amortization	(228.8)	(219.9)
Intangible Assets, Net (Excluding Goodwill)	178.5	188.3
Use Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	10.8	10.9
Accumulated Amortization	(5.8)	(5.5)
Intangible Assets, Net (Excluding Goodwill)	5	5.4
Canadian licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	444.1	480.3
Accumulated Amortization	0	0
Intangible Assets, Net (Excluding Goodwill)	$ 444.1	$ 480.3

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	$ 5,811.7		$ 5,885.6
Goodwill	7,388.5		7,865
Amortization of intangible assets	62.3	$ 57.1
Finite-Lived Intangible Assets, Future Amortization Expense
Estimated amortization expense, 2012	176.6
Estimated amortization expense, 2013	231.8
Estimated amortization expense, 2014	225.9
Estimated amortization expense, 2015	222.8
Estimated amortization expense, 2016	218.2
Estimated amortization expense, Thereafter	2,299.9
LabCorp Diagnostics [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill	3,711.2		3,721.5
Covance Drug Development [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 3,677.3		$ 4,143.5

DEBT (Short-term borrowings and

DEBT (Short-term borrowings and current portion of long-term debt) (Table) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Short-term Debt [Line Items]
Line of Credit Facility, Fair Value of Amount Outstanding		$ 375
Total short-term borrowings and current portion of long-term debt	$ 417.4	415.2
Short-term borrowings and current portion of long-term debt	Short-term borrowings and the current portion of long-term debt at March 31, 2020 , and December 31, 2019 , consisted of the following: March 31, December 31, 2019 4.625% senior notes due 2020 $ 415.5 $ 413.7 Debt issuance costs (0.3 ) (0.7 ) Current portion of note payable 2.2 2.2 Total short-term borrowings and current portion of long-term debt $ 417.4 $ 415.2
Senior notes due 2020 [Member]
Short-term Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.625%
Senior notes due 2022 [Member]
Short-term Debt [Line Items]
Senior Notes, Noncurrent	$ 500	$ 500

DEBT (Long-term debt) (Details)

DEBT (Long-term debt) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Dec. 19, 2014
Debt Instrument [Line Items]
Long-term Debt [Text Block]	Long-term debt at March 31, 2020 , and December 31, 2019 , consisted of the following: March 31, December 31, 2019 3.20% senior notes due 2022 $ 500.0 $ 500.0 3.75% senior notes due 2022 500.0 500.0 4.00% senior notes due 2023 300.0 300.0 3.25% senior notes due 2024 600.0 600.0 3.60% senior notes due 2025 1,000.0 1,000.0 3.60% senior notes due 2027 600.0 600.0 4.70% senior notes due 2045 900.0 900.0 2.30% senior notes due 2024 400.0 400.0 2.95% senior notes due 2029 650.0 650.0 2019 Term Loan 375.0 375.0 Debt issuance costs (41.3 ) (42.2 ) Note payable 6.5 7.0 Total long-term debt $ 5,790.2 $ 5,789.8
Long-term Debt, Excluding Current Maturities	$ 5,790.2	$ 5,789.8
Line of Credit Facility, Fair Value of Amount Outstanding		375
Line of Credit Facility, Maximum Borrowing Capacity			$ 1,000
Credit Facility Option to Increase			350
Credit Facility, Maximum Swing Line Borrowings			100
2019 Term Loan [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Fair Value of Amount Outstanding	$ 375
Senior notes due 2020 [Member]
Debt Instrument [Line Items]
Stated interest rate percentage	4.625%
Senior notes due 2022 [Member]
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	$ 500	500
Senior Notes, Noncurrent	500	500
Senior notes due 2023 [Member]
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	300	300
Senior notes due 2025 [Member] [Member]
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	1,000	1,000
Senior notes due 2045 [Member]
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	$ 900	$ 900
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Credit Facility, Maximum Letters of Credit			$ 150
Prime Rate [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Interest Rate Description	0.00% to 0.25%
2019 Term Loan [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage	1.79%

DEBT (Senior Notes) (Details)

DEBT (Senior Notes) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Dec. 19, 2014
Debt Instrument [Line Items]
Short term debt issuance costs	$ 0.3	$ 0.7
Long-term Debt, Excluding Current Maturities	5,790.2	5,789.8
Line of Credit Facility, Maximum Borrowing Capacity			$ 1,000
Credit Facility Option to Increase			350
Credit Facility, Maximum Swing Line Borrowings			$ 100
Fair Value Hedges, Net	$ 3.3	1.5
Debt Instrument, Basis Spread on Variable Rate	2.298%
Line of Credit Facility, Fair Value of Amount Outstanding		375
Long term debt issuance costs	$ 41.3	42.2
Notes Payable	2.2	2.2
Debt, Current	417.4	415.2
Foreign Currency Contract, Asset, Fair Value Disclosure		3.2
4.625% Senior notes due 2020	415.5	413.7
2.30% senior notes due 2024	400	400
2.95% senior notes due 2029	650	650
Senior notes due 2023 [Member]
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	300	300
Senior notes due 2024 [Member] [Member]
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	600	600
Senior notes due 2027 [Member]
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	600	600
Senior notes due 2045 [Member]
Debt Instrument [Line Items]
Long-term Debt, Excluding Current Maturities	900	$ 900
2019 Term Loan [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Fair Value of Amount Outstanding	$ 375
Senior notes due 2020 [Member]
Debt Instrument [Line Items]
Stated interest rate percentage	4.625%

DEBT (Credit Facilities) (Detai

DEBT (Credit Facilities) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)Rate	Dec. 31, 2019USD ($)	May 07, 2020Rate	Jun. 03, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 19, 2014USD ($)
Line of Credit Facility [Line Items]
2019 Term Loan				$ 850
Line of Credit Facility, Remaining Borrowing Capacity	$ 923.7
Senior Notes Became Due During Quarter		$ 412.2
Cash and cash equivalents	323.6	337.5			$ 348.8	$ 426.8
Long-term Debt, Excluding Current Maturities	5,790.2	5,789.8
Line of Credit Facility, Fair Value of Amount Outstanding		375
Revolving Credit Facility, maximum borrowing capacity							$ 1,000
Notes Payable	2.2	2.2
Debt, Current	417.4	415.2
Credit Facility Option to Increase							350
Credit Facility, Maximum Swing Line Borrowings							100
Notes Payable	6.5	7
Senior notes due 2027 [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Excluding Current Maturities	600	600
Senior notes due 2024 [Member] [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Excluding Current Maturities	$ 600	600
Senior notes due 2020 [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.625%
Senior notes due 2045 [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Excluding Current Maturities	$ 900	900
Senior notes due 2022 [Member]
Line of Credit Facility [Line Items]
Senior Notes, Noncurrent	500	500
Long-term Debt, Excluding Current Maturities	$ 500	$ 500
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Credit Facility, Maximum Letters of Credit							$ 150
Line of Credit Facility, Interest Rate at Period End | Rate	1.97%
Prime Rate [Member] | 2019 Term Loan [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate Description	0.0% to 0.175%
Prime Rate [Member] | Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate Description	0.00% to 0.25%
London Interbank Offered Rate (LIBOR) [Member] | 2019 Term Loan [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate Description	0.55% to 1.175%
Subsequent Event [Member] | Term Loan and Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Debt to EBITDA (Leverage) Ratio Quarter Ending 1 Year From Present			4.50
Subsequent Event [Member] | 2019 Term Loan [Member]
Line of Credit Facility [Line Items]
Term Loan Accrue Interest per Annum at Libor Plus Margin Percentage | Rate			1.175%
Term Loan Accrue Interest Per Annum Base Rate Plus Percentage | Rate			0.175%
Subsequent Event [Member] | Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Revolving Credit Facility Accrue Interest per Annum at Libor Plus Margin Percentage | Rate			1.25%
Revolving Credit Facility Accrue Interest Per Annum Base Rate Plus Percentage | Rate			0.25%
Revolving Credit Facility Fee Percentage Required to Pay on Outstanding Commitments | Rate			0.25%
Subsequent Event [Member] | Maximum [Member] | Term Loan and Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Debt to EBITDA (Leverage) Ratio Next Three Quarters			5

PREFERRED STOCK AND COMMON SH_2

PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020
Class of Stock [Line Items]
Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased			800
Rollforward of common shares issued
Stock Repurchased During Period, Shares	0.6
Common stock repurchase average purchase price per share	$ 178.85
Payments for Repurchase of Common Stock	$ 100	$ 100.1
Rollforward of Share Repurchase Program
Purchase of common stock	(100)	$ (100.1)
Outstanding common stock repurchase authorization, ending balance	$ 900
Common Shares Outstanding Rollforward [Abstract]
Common shares outstanding, beginning balance (in shares)	97.2
Common shares outstanding, ending balance (in shares)	97.1
Rollforward of common shares held in treasury
Treasury Stock, Carrying Basis			$ 100
Common Stock, Shares Authorized			265
Common Stock, Par or Stated Value Per Share			$ 0.10
Preferred Stock, Shares Authorized			30
Preferred Stock, Par or Stated Value Per Share			$ 0.10
Preferred Stock, Shares Outstanding			0
Common Stock [Member]
Rollforward of common shares issued
Common shares issued, beginning balance (in shares)	97.2
Commons Stock Issued During Period Shares Employee Stock Plans	0.5
Stock Repurchased and Retired During Period, Shares	(0.6)
Common shares issued, ending balance (in shares)	97.1
Common Stock, Shares, Issued	97.1		97.1
Common Shares Outstanding Rollforward [Abstract]
Commons Stock Issued During Period Shares Employee Stock Plans	0.5
Stock Repurchased and Retired During Period, Shares	(0.6)
Commons Stock Issued During Period Shares Employee Stock Plans	0.5
Rollforward of common shares held in treasury
Stock Repurchased and Retired During Period, Shares	(0.6)

PREFERRED STOCK AND COMMON SH_3

PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY PREFERRED STOCK AND COMMON SHAREHOLDERS' EQUITY - Accumulated Other Comprehensive Earnings (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	The components of accumulated other comprehensive earnings (loss) are as follows: Foreign Currency Translation Adjustments Net Benefit Plan Adjustments Accumulated Other Comprehensive Earnings (Loss) Balance as of December 31, 2019 $ (285.4 ) $ (87.0 ) $ (372.4 ) Current year adjustments (147.5 ) 2.7 (144.8 ) Tax effect of adjustments — (0.7 ) (0.7 ) Balance as of March 31, 2020 $ (432.9 ) $ (85.0 ) $ (517.9 )
Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax	$ 2.7
Other Comprehensive Income (Loss), before Reclassifications, before Tax	(144.8)
Accumulated Other Comprehensive Earnings [Roll Forward]
Foreign Currency Translation Adjustments, Beginning balance	(285.4)
Other comprehensive income before reclassifications	(147.5)
Tax effect of adjustments	0
Foreign Currency Translation Adjustments, Ending balance	(432.9)
Net Benefit Plan Adjustments, Beginning balance	(87)
Tax effect of adjustments	(0.7)
Net Benefit Plan Adjustments, Ending balance	(85)
Accumulated Other Comprehensive Earnings, Beginning balance	(372.4)
Other comprehensive income before reclassifications	(147.5)
Tax effect of adjustments	(0.7)	$ (0.7)
Accumulated Other Comprehensive Earnings, Ending balance	$ (517.9)

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, Tax Contingency, Percent	50.00%
Gross unrecognized income tax benefits	$ 32.3	$ 31.7
Accrued interest and penalties related to unrecognized income tax benefits	$ 6	$ 5.5

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details)	Mar. 31, 2020USD ($)
Loss Contingencies [Line Items]
Number of Additional Parties Not Providing Consent	40
Damages Per Violation	$ 500

PENSION AND POSTRETIREMENT PL_2

PENSION AND POSTRETIREMENT PLANS (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Defined Benefit Plan Disclosures [Line Items]
Minimum non-elective contribution (NEC) % for the 401(K) plan (in hundredths)	3.00%
Discretionary Contribution Percentage Maximum	3.00%
Defined Benefit Plan and Postretirement Plan Disclosure
Schedule of Pensions and Postretirement Plans	The effect on operations for the Company Plan and the PEP is summarized as follows: Three Months Ended March 31, 2020 2019 Service cost for administrative expenses $ 1.3 $ 1.0 Interest cost on benefit obligation 2.8 3.5 Expected return on plan assets (3.7 ) (3.8 ) Net amortization and deferral 2.6 2.6 Defined benefit plan costs $ 3.0 $ 3.3
Pension And Postretirement Plans	PENSION AND POSTRETIREMENT PLANS Retirement Plans All employees eligible for the LCD defined-contribution retirement plan (LCD 401K Plan) receive a minimum 3% non-elective contribution (NEC) concurrent with each payroll period. Employees are not required to make a contribution to the LCD 401K Plan to receive the NEC. The NEC is non-forfeitable and vests immediately. The LCD 401K Plan also permits discretionary contributions by the Company of 1% to 3% of pay for eligible employees based on service. For the three months ended March 31, 2020 , and 2019 , total expense for the LCD 401K Plan was $13.5 and $16.0 , respectively. All of the CDD U.S. employees are eligible to participate in the CDD 401K Plan, which is available on a voluntary basis and features a maximum 4.5% Company match, based upon a percentage of the employee’s contributions. The Company incurred expense of $23.4 and $19.9 for the Covance 401K plan during the three months ended March 31, 2020 , and 2019 , respectively. The Company also maintains several other small 401K plans associated with companies acquired over the last several years. Pension Plans The Company has a defined-benefit retirement plan (Company Plan) and a nonqualified supplemental retirement plan (PEP). Both plans have been closed to new participants since December 31, 2009. Employees participating in the Company Plan and PEP no longer earn service-based credits, but continue to earn investment credits. The Company Plan covers substantially all employees employed prior to December 31, 2009. The benefits to be paid under the Company Plan are based on years of credited service through December 31, 2009, interest credits and average compensation. The Company's policy is to fund the Company Plan with at least the minimum amount required by applicable regulations. The PEP covers a portion of the Company's senior management group. Prior to 2010, the PEP provided for the payment of the difference, if any, between the amount of any maximum limitation on annual benefit payments under the Employee Retirement Income Security Act of 1974 and the annual benefit that would be payable under the Company Plan but for such limitation. Effective January 1, 2010, employees participating in the PEP no longer earn service-based credits. The PEP is an unfunded plan. The effect on operations for the Company Plan and the PEP is summarized as follows: Three Months Ended March 31, 2020 2019 Service cost for administrative expenses $ 1.3 $ 1.0 Interest cost on benefit obligation 2.8 3.5 Expected return on plan assets (3.7 ) (3.8 ) Net amortization and deferral 2.6 2.6 Defined benefit plan costs $ 3.0 $ 3.3 The service cost component of net periodic pension cost and net periodic post-retirement benefit cost is included in operating expenses with other employee compensation costs. The other components of net benefit cost, including amortization or prior service cost/credit and settlement and curtailment effects are included in other, net non-operating expenses. During the three months ended March 31, 2020 , the Company made no contributions to the Company Plan. The related net pension obligation for the Company Plan and PEP was $93.1 and $93.4 as of March 31, 2020 and December 31, 2019 , respectively. As a result of the Covance acquisition, the Company sponsors two defined benefit pension plans for the benefit of its employees at two U.K. subsidiaries (U.K. Plans) and one defined benefit pension plan for the benefit of its employees at a German subsidiary (German Plan), all of which are legacy plans of previously acquired companies. The U.K. Plans were closed to future accrual as of December 31, 2019. Benefit amounts for all three plans are based upon years of service and compensation; however, the U.K. Plans were based on service and compensation through December 31, 2019. The German Plan is unfunded while the U.K. Plans are funded. The Company’s funding policy has been to contribute annually a fixed percentage of the eligible employee's salary, and additional amounts, at least equal to the local statutory funding requirements. As a result of the Envigo acquisition, the Company assumed a defined benefit pension plan for the benefit of Envigo's U.K. employees (the Envigo Plan), which is a legacy plan of a company previously acquired by Envigo. The Envigo Plan is a funded plan that is closed to future accrual. The Company’s funding policy has been to contribute amounts at least equal to the local statutory funding requirements. The related net pension obligation for these plans inclusive of the U.K. Plans, German Plan, and the Envigo Plan, was $88.6 and $99.1 as of March 31, 2020 and December 31, 2019 , respectively.
Defined Benefit Plan, Funded (Unfunded) Status of Plan	$ (93.1)		$ (93.4)
Pension and Other Postretirement Plans Costs [Member]
Defined Benefit Plan and Postretirement Plan Disclosure
Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation	88.6		$ 99.1
Pension Plan [Member]
Defined Benefit Plan and Postretirement Plan Disclosure
Service cost for benefits earned	1.3	$ 1
Interest cost on benefit obligation	2.8	3.5
Expected return on plan assets	(3.7)	(3.8)
Net amortization and deferral	2.6	2.6
Defined benefit/postretirement plan costs	3	3.3
Covance [Member]
Defined Benefit Plan Disclosures [Line Items]
Defined contribution retirement plan cost	$ (23.4)	$ (19.9)

PENSION AND POSTRETIREMENT PL_3

PENSION AND POSTRETIREMENT PLANS Defined Contribution Plans (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Non Elective Contribution	3.00%
Discretionary Contribution Percentage Minimum	1.00%
Defined Contribution Plan Total Expense	$ 13.5	$ 16
Discretionary Contribution Percentage Maximum	3.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	4.50%
Covance [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Cost	$ 23.4	$ 19.9

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Sep. 30, 2019USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Financial Statement Captions [Line Items]
Number of Measurement Funds Available For Participant Election	16
Noncontrolling interest puts	$ 14.6	$ 15.8
Fair market value of senior notes	6,007.2	6,140.6
Notes Receivable, Fair Value Disclosure			$ 110
Cash Surrender Value, Fair Value Disclosure	68	80.2
Fair Value Liabilities Measured On Recurring Basis Deferred Compensation Liability	66.7	76.7
Contingent Consideration Classified as Equity, Fair Value Disclosure	6.4	9.9
Fair Value Hedges, Net	3.3	1.5
Foreign Currency Contract, Asset, Fair Value Disclosure		3.2
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	(1.4)
Contingent consideration adjustment	(2.1)
Equity Securities, FV-NI		9.1
Level 1 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Financial Statement Captions [Line Items]
Noncontrolling interest puts	0	0
Cash Surrender Value, Fair Value Disclosure	0	0
Contingent Consideration Classified as Equity, Fair Value Disclosure	0	0
Fair Value Hedges, Net	0	0
Foreign Currency Contract, Asset, Fair Value Disclosure		0	$ 0
Equity Securities, FV-NI		9.1
Fair Value, Inputs, Level 2 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Financial Statement Captions [Line Items]
Noncontrolling interest puts	14.6	15.8
Cash Surrender Value, Fair Value Disclosure	68	80.2
Fair Value Liabilities Measured On Recurring Basis Deferred Compensation Liability	0	0
Contingent Consideration Classified as Equity, Fair Value Disclosure	0	0
Fair Value Hedges, Net		1.5
Foreign Currency Contract, Asset, Fair Value Disclosure		3.2
Equity Securities, FV-NI		0
Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Financial Statement Captions [Line Items]
Noncontrolling interest puts	0	0
Cash Surrender Value, Fair Value Disclosure	0	0
Fair Value Liabilities Measured On Recurring Basis Deferred Compensation Liability	0	0
Contingent Consideration Classified as Equity, Fair Value Disclosure	6.4	9.9
Fair Value Hedges, Net	0	0
Foreign Currency Contract, Asset, Fair Value Disclosure	$ 0	0
Equity Securities, FV-NI		$ 0

DERIVATIVE INSTRUMENTS AND HE_2

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge	$ 19.9
Long-term Debt, Excluding Current Maturities	$ 5,790.2		$ 5,789.8
Debt Instrument, Basis Spread on Variable Rate	2.298%
Foreign Currency Contract, Asset, Fair Value Disclosure			3.2
Foreign Currency Contracts, Liability, Fair Value Disclosure	$ 23.1
Fair Value Hedge Liabilities	(3.3)		(1.5)
Senior notes due 2020 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
4.625% Senior notes due 2020	303.3		301.5
Interest Rate Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Other Comprehensive Income (Loss)	1.8	$ 2.5
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	0	0
Fair Value Hedge Assets	3.3		1.5
Fair Value Hedge Liabilities	0		0
Currency Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Other Comprehensive Income (Loss)	19.9	11.5
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	0	$ 0
Fair Value Hedge Assets	23.1		3.2
Fair Value Hedge Liabilities	0		0
Senior notes due 2022 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Long-term Debt, Excluding Current Maturities	500		500
Cross currency swap maturing 2022 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount	300
Senior notes due 2025 [Member] [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount	$ 300
Senior notes due 2020 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.625%
Senior Long Term Notes Due2020 Member
Derivative Instruments, Gain (Loss) [Line Items]
Long-term Debt, Excluding Current Maturities	$ 300		300
Senior notes due 2025 [Member] [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Long-term Debt, Excluding Current Maturities	1,000		1,000
Senior notes due 2027 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Long-term Debt, Excluding Current Maturities	600		600
Fair Value, Inputs, Level 2 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure			$ 3.2
Foreign Currency Contracts, Liability, Fair Value Disclosure	$ 23.1

SUPPLEMENTAL CASH FLOW INFORM_3

SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Sep. 30, 2019
Debt Conversion [Line Items]
Decrease in Capital Expenditures Incurred but not yet Paid	$ (14)
Capital Expenditures Incurred but Not yet Paid		$ (12.1)
Notes Receivable, Fair Value Disclosure			$ 110
Cash paid during period for:
Interest	80	99.7
Income taxes, net of refunds	5.8	(2.2)
Disclosure of non-cash financing and investing activities:
Conversion of zero-coupon convertible debt	$ 0	$ 7.3

BUSINESS ACQUISITIONS (Details)

BUSINESS ACQUISITIONS (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Sep. 30, 2019	Dec. 31, 2019	Jun. 03, 2019
Business Combination Purchase Price Allocation [Line Items]
Revenues	$ 2,823.8	$ 2,791.2
Operating Income (Loss)	(192.6)	318.2
Net Income (Loss) Attributable to Parent	(317.2)	185.6
Goodwill	7,388.5			$ 7,865
Cash payments for laboratory-related assets	106.6	94.2
Payments to Acquire Businesses, Net of Cash Acquired	0	47.3
Notes Receivable, Fair Value Disclosure			$ 110
Total acquisition consideration (cash, stock, notes, etc.)					$ 711
Gain (Loss) on Disposition of Assets			(12.2)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	0
Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	$ (11.4)				(15.1)
Payments to Acquire Businesses, Net of Cash Acquired			$ 601
Notes Receivable, Fair Value Disclosure					110
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	11 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	$ (11.9)				(16.5)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other	(26.2)				(26.5)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	4.5				4.5
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets	9.8				3.5
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets	(14)				(25.5)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	124.9				99.1
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	(380.8)				(432.2)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	141.4				125.8
Indefinite-Lived Trade Names					0.6
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets	9.9				9.9
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	(734.8)				(759.2)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable	(15.2)				(15.4)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other	(10.1)				(11.6)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue	49.9				49.9
Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation	0				(15)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities	(58.6)				(66.3)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	(133.8)				(158.2)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	601				$ 601
Trade Names [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	0.6
Customer Relationships [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	140.8
Trademarks and Trade Names [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Indefinite-Lived Trade Names	0
Cash and Cash Equivalents [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	(3.7)
Accounts Receivable [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	(4.6)
Other Current Assets [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other	(0.3)
Inventories [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	0
Prepaid Expenses and Other Current Assets [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets	6.3
Property, Plant and Equipment [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	25.8
Deferred Tax Asset [Domain] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets	(11.5)
Goodwill [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	(51.4)
Customer Relationships [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	15
Other Noncurrent Assets [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets	0
Assets [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	(24.4)
Accounts Payable [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable	(0.2)
Accrued Liabilities [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other	(1.5)
Deferred Revenue [Domain] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue	0
Other Liabilities [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation	(15)
Other Noncurrent Liabilities [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities	(7.7)
Liability [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	(24.4)
Covance Drug Development [Member]
Business Combination Purchase Price Allocation [Line Items]
Revenues	1,143.8	1,074.7
Operating Income (Loss)	(338.7)	$ 88
Goodwill	3,677.3			$ 4,143.5
Covance Drug Development [Member] | Envigo [Member]
Business Combination Purchase Price Allocation [Line Items]
impairment of floating rate note receivable	$ 5

BUSINESS ACQUISITIONS Busines_2

BUSINESS ACQUISITIONS Business Acquisitions in the Aggregate (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Sep. 30, 2019	Dec. 31, 2019	Jun. 03, 2019
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue	$ 2,832.6
Gain (Loss) on Disposition of Assets			$ (12.2)
Revenues	2,823.8	$ 2,791.2
Payments to Acquire Businesses, Net of Cash Acquired	0	$ 47.3
Goodwill	7,388.5			$ 7,865
Business Acquisition, Pro Forma Net Income (Loss)	188
Envigo [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	380.8				$ 432.2
Payments to Acquire Businesses, Net of Cash Acquired			$ 601
Other acquirees [Member]
Business Acquisition [Line Items]
Goodwill, Acquired During Period	22.1
Payments to Acquire Businesses, Net of Cash Acquired	47.3
Finite-lived Intangible Assets Acquired	$ 24.8

BUSINESS ACQUISITIONS DISPOSITI

BUSINESS ACQUISITIONS DISPOSITIONS (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents	$ (323.6)	$ (337.5)	$ (348.8)	$ (426.8)
Accounts Receivable, after Allowance for Credit Loss, Current	1,482.2	1,543.9
Unbilled Contracts Receivable	478.1	481.4
Supplies inventories	254	244.7
Prepaid expenses and other	353.2	373.7
Property, plant and equipment, net	2,609.6	2,636.6
Goodwill	7,388.5	7,865
Intangible Assets, Net (Excluding Goodwill)	3,905.1	4,034.5
Other assets, net	430.6	435.4
Accounts Payable, Current	568.7	632.3
Accrued Liabilities, Current	828.1	942.4
Deferred Revenue, Current	432.9	451
Deferred income taxes and other tax liabilities	943.1	942.8
Commitments and contingent liabilities	$ 369.4	$ 383.2

BUSINESS SEGMENT INFORMATION _2

BUSINESS SEGMENT INFORMATION Business Segment Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Percent of Revenue Contributed	100.00%	100.00%
Intercompany revenue elimination	$ (22)	$ (5.5)
Revenues	2,823.8	2,791.2
Operating Income (Loss)	(192.6)	318.2
Earnings before income taxes	(267.7)	254.7
Provision for income taxes	(267.7)	254.7
Provision for income taxes	49.2	68.8
Net earnings	(316.9)	185.9
Net income attributable to Laboratory Corporation of America Holdings	(0.3)	(0.3)
Nonoperating Income (Expense)	(75.1)	(63.5)
Net Income (Loss) Attributable to Parent	(317.2)	185.6
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Operating Income (Loss)	$ (42.3)	$ (38.1)
LabCorp Diagnostics [Member]
Segment Reporting Information [Line Items]
Percent of Revenue Contributed	60.00%	62.00%
Revenues	$ 1,702	$ 1,722
Operating Income (Loss)	$ 188.4	268.3
Covance Drug Development [Member]
Segment Reporting Information [Line Items]
Percent of Revenue Contributed	40.00%
Revenues	$ 1,143.8	1,074.7
Operating Income (Loss)	$ (338.7)	$ 88

REVENUE Disaggregated Revenue T

REVENUE Disaggregated Revenue Table (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Accounts Receivable, Allowance for Credit Loss	$ 28.9		$ 19
Unbilled Services, Allowance for Credit Loss	2.4		2.3
Note Receivable, Allowance for Credit Loss	10		0
Allowance for Credit Loss	41.3		21.3
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings	7
Accounts Receivable, Credit Loss Expense (Reversal)	8.5
Unbilled Services, Credit Loss Expense (Reversal)	0
Note Receivable, Credit Loss Expense (Reversal)	5
Credit Loss Expense (Reversal)	13.5
Allowance for Credit Loss, Write Off	0.5
Increase Decrease in Operating Income Loss	$ (17)
Sales Commission Amortization Period Minimum	12 months
Deferred Revenue, Revenue Recognized	$ 121.8	$ 103.6
Contract with Customer, Asset, before Allowance for Credit Loss	480.6		483.7
Revenue, Remaining Performance Obligation, Amount	$ 4,494.9
Percent of remaining performance obligations recognized as revenue in next year	35.00%
Long Term Contracts Duration Minimum	1 year
Long Term Contracts Duration Maximum	8 years
Contract with Customer, Performance Obligation Satisfied in Previous Period	$ 9.7	39.7
Contract with Customer, Liability	430.9		449.2
Capitalized Contract Cost, Amortization	3	1.8
Accrued Sales Commission	30.3		28.6
Capitalized Contract Cost, Net	13.8		14.9
Amount of Deferred Costs Related to Long-term Contracts	44.1		43.5
Amortization of Deferred Sales Commissions	5.3	$ 4.5
Unbilled Contracts Receivable	$ 478.1		481.4
Percent of Revenue Contributed	100.00%	100.00%
Sales Commission Amortization Period Maximum	57 months
Medicare and Medicaid [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	8.00%	9.00%
UNITED STATES
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	77.00%	78.00%
CANADA
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	3.00%	3.00%
UNITED KINGDOM
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	5.00%	4.00%
SWITZERLAND
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	5.00%	5.00%
Europe [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	3.00%	3.00%
Other countries [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	7.00%	7.00%
LabCorp Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	60.00%	62.00%
LabCorp Diagnostics [Member] | Client [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	17.00%	17.00%
LabCorp Diagnostics [Member] | Self-Pay [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	7.00%	8.00%
LabCorp Diagnostics [Member] | Third party [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	28.00%	28.00%
LabCorp Diagnostics [Member] | UNITED STATES
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	57.00%	59.00%
LabCorp Diagnostics [Member] | UNITED STATES | Client [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	16.00%	16.00%
LabCorp Diagnostics [Member] | UNITED STATES | Self-Pay [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	7.00%	8.00%
LabCorp Diagnostics [Member] | UNITED STATES | Medicare and Medicaid [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	8.00%	9.00%
LabCorp Diagnostics [Member] | UNITED STATES | Third party [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	26.00%	26.00%
LabCorp Diagnostics [Member] | CANADA
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	3.00%	3.00%
LabCorp Diagnostics [Member] | CANADA | Client [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	1.00%	1.00%
LabCorp Diagnostics [Member] | CANADA | Self-Pay [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | CANADA | Medicare and Medicaid [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | CANADA | Third party [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	2.00%	2.00%
LabCorp Diagnostics [Member] | UNITED KINGDOM
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | UNITED KINGDOM | Client [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | UNITED KINGDOM | Self-Pay [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | UNITED KINGDOM | Medicare and Medicaid [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | UNITED KINGDOM | Third party [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | SWITZERLAND
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | SWITZERLAND | Client [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | SWITZERLAND | Self-Pay [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | SWITZERLAND | Medicare and Medicaid [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | SWITZERLAND | Third party [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | Europe [Member] | Client [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | Europe [Member] | Self-Pay [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | Europe [Member] | Medicare and Medicaid [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | Europe [Member] | Third party [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | Other countries [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | Other countries [Member] | Medicare and Medicaid [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
LabCorp Diagnostics [Member] | Other countries [Member] | Third party [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
Covance Drug Development [Member]
Disaggregation of Revenue [Line Items]
Unbilled Contracts Receivable	$ 758.6		$ 771.1
Percent of Revenue Contributed	40.00%
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	40.00%	38.00%
Covance Drug Development [Member] | UNITED STATES | Biopharmaceutical and medical device companies [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	20.00%	19.00%
Covance Drug Development [Member] | CANADA | Biopharmaceutical and medical device companies [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	0.00%	0.00%
Covance Drug Development [Member] | UNITED KINGDOM | Biopharmaceutical and medical device companies [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	5.00%	4.00%
Covance Drug Development [Member] | SWITZERLAND | Biopharmaceutical and medical device companies [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	5.00%	5.00%
Covance Drug Development [Member] | Europe [Member] | Biopharmaceutical and medical device companies [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	3.00%	3.00%
Covance Drug Development [Member] | Other countries [Member] | Biopharmaceutical and medical device companies [Member]
Disaggregation of Revenue [Line Items]
Percent of Revenue Contributed	7.00%	7.00%
Minimum [Member]
Disaggregation of Revenue [Line Items]
Capitalized Contract Cost, Amortization Period	24 months
Maximum [Member]
Disaggregation of Revenue [Line Items]
Capitalized Contract Cost, Amortization Period	60 months
Notes Receivable [Member]
Disaggregation of Revenue [Line Items]
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings	$ 5
Allowance for Credit Loss, Write Off	0
Unbilled Contracts Receivable [Member]
Disaggregation of Revenue [Line Items]
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings	0.2
Allowance for Credit Loss, Write Off	0.1
Accounts Receivable [Member]
Disaggregation of Revenue [Line Items]
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings	1.8
Allowance for Credit Loss, Write Off	$ 0.4

Subsequent Event (Details)

Subsequent Event (Details) - Subsequent Event [Member] $ in Millions	1 Months Ended
	Apr. 30, 2020USD ($)	May 07, 2020Rate
Subsequent Event [Line Items]
Cash Payment Received Appropriated by U.S. Congress Covid-19 | $	$ 56
Term Loan and Revolving Credit Facility [Member]
Subsequent Event [Line Items]
Debt to EBITDA (Leverage) Ratio Quarter Ending 1 Year From Present		4.50
Revolving Credit Facility [Member]
Subsequent Event [Line Items]
Revolving Credit Facility Accrue Interest per Annum at Libor Plus Margin Percentage		1.25%
Revolving Credit Facility Accrue Interest Per Annum Base Rate Plus Percentage		0.25%
Revolving Credit Facility Fee Percentage Required to Pay on Outstanding Commitments		0.25%
Maximum [Member] | Term Loan and Revolving Credit Facility [Member]
Subsequent Event [Line Items]
Debt to EBITDA (Leverage) Ratio Next Three Quarters		5

Leases (Details)

Leases (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Operating Lease, Liability, Current	$ 202.7	$ 206.5
Operating Lease, Liability, Noncurrent	609.8	596.6
Finance Lease, Liability, Current	8.2	8.4
Finance Lease, Liability, Noncurrent	$ 89.3	$ 91.1